{ "instance": { "fs42022a1_biotechacq.htm": { "axisCustom": 2, "axisStandard": 17, "contextCount": 234, "dts": { "calculationLink": { "local": [ "biot-20211231_cal.xml" ] }, "definitionLink": { "local": [ "biot-20211231_def.xml" ] }, "inline": { "local": [ "fs42022a1_biotechacq.htm" ] }, "labelLink": { "local": [ "biot-20211231_lab.xml" ] }, "presentationLink": { "local": [ "biot-20211231_pre.xml" ] }, "schema": { "local": [ "biot-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 906, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 174, "http://www.biotechacquisitionco.com/20211231": 21, "http://xbrl.sec.gov/dei/2021": 3, "total": 198 }, "keyCustom": 178, "keyStandard": 388, "memberCustom": 30, "memberStandard": 30, "nsprefix": "biot", "nsuri": "http://www.biotechacquisitionco.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Initial Public Offering", "role": "http://www.biotechacquisitionco.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Private Placement", "role": "http://www.biotechacquisitionco.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Related Party Transactions", "role": "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Commitments and Contingencies", "role": "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Shareholders\u2019 (DEFICIT) Equity", "role": "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquity", "shortName": "Shareholders\u2019 (DEFICIT) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Warrants", "role": "http://www.biotechacquisitionco.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Fair Value Measurements", "role": "http://www.biotechacquisitionco.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Subsequent Events", "role": "http://www.biotechacquisitionco.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:TheCompanyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - The Company", "role": "http://www.biotechacquisitionco.com/role/TheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:TheCompanyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Balance Sheet Components", "role": "http://www.biotechacquisitionco.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Income Taxes", "role": "http://www.biotechacquisitionco.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:TermLoanAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Term Loan Agreement", "role": "http://www.biotechacquisitionco.com/role/TermLoanAgreement", "shortName": "Term Loan Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:TermLoanAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Convertible Notes", "role": "http://www.biotechacquisitionco.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:CommonStockWarrants", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Common Stock Warrants", "role": "http://www.biotechacquisitionco.com/role/CommonStockWarrants", "shortName": "Common Stock Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:CommonStockWarrants", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Convertible Preferred Stock", "role": "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStock", "shortName": "Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Common Stock", "role": "http://www.biotechacquisitionco.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:StockOptionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Stock Option Plan", "role": "http://www.biotechacquisitionco.com/role/StockOptionPlan", "shortName": "Stock Option Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:StockOptionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - License and Research and Development Agreements", "role": "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreements", "shortName": "License and Research and Development Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Acquisition of ATXCo", "role": "http://www.biotechacquisitionco.com/role/AcquisitionofATXCo", "shortName": "Acquisition of ATXCo", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Net Loss Per Share", "role": "http://www.biotechacquisitionco.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Income Taxes (Tables)", "role": "http://www.biotechacquisitionco.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Term Loan Agreement (Tables)", "role": "http://www.biotechacquisitionco.com/role/TermLoanAgreementTables", "shortName": "Term Loan Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Common Stock Warrants (Tables)", "role": "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables", "shortName": "Common Stock Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Convertible Preferred Stock (Tables)", "role": "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockTables", "shortName": "Convertible Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Common Stock (Tables)", "role": "http://www.biotechacquisitionco.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c9", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "role": "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c9", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Stock Option Plan (Tables)", "role": "http://www.biotechacquisitionco.com/role/StockOptionPlanTables", "shortName": "Stock Option Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.biotechacquisitionco.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Description of Organization and Business Operations (Details)", "role": "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "shortName": "Description of Organization and Business Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "biot:ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleLeasebackTransactionGrossProceedsFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of condensed balance sheet are reconciled", "role": "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of condensed balance sheet are reconciled", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "biot:ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleLeasebackTransactionGrossProceedsFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c71", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityNetIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income per common share", "role": "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income per common share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c71", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityNetIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "2", "first": true, "lang": null, "name": "biot:PurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Initial Public Offering (Details)", "role": "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails", "shortName": "Initial Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "2", "first": true, "lang": null, "name": "biot:PurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockDescriptionOfTransaction", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Private Placement (Details)", "role": "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails", "shortName": "Private Placement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockDescriptionOfTransaction", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c79", "decimals": "2", "first": true, "lang": null, "name": "biot:IssuedOutstandingPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Related Party Transactions (Details)", "role": "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c79", "decimals": "2", "first": true, "lang": null, "name": "biot:IssuedOutstandingPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c87", "decimals": null, "first": true, "lang": "en-US", "name": "biot:UnderwritingAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c87", "decimals": null, "first": true, "lang": "en-US", "name": "biot:UnderwritingAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c34", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders\u2019 (Deficit) Equity", "role": "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Changes in Shareholders\u2019 (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c34", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Shareholders\u2019 (DEFICIT) Equity (Details)", "role": "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails", "shortName": "Shareholders\u2019 (DEFICIT) Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "biot:PreferenceSharesIssuedOrOutstanding", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:PublicWarrantExpired", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Warrants (Details)", "role": "http://www.biotechacquisitionco.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "biot:PublicWarrantExpired", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c93", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Fair Value Measurements (Details) - Schedule of assets that are measured at fair value on a recurring basis", "role": "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "shortName": "Fair Value Measurements (Details) - Schedule of assets that are measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c93", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c95", "decimals": "2", "first": true, "lang": null, "name": "biot:MarketPriceOfPublicShares", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Fair Value Measurements (Details) - Schedule of binomial lattice model for warrants", "role": "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable", "shortName": "Fair Value Measurements (Details) - Schedule of binomial lattice model for warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c95", "decimals": "2", "first": true, "lang": null, "name": "biot:MarketPriceOfPublicShares", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c63", "decimals": "0", "first": true, "lang": null, "name": "biot:InitialMeasurementFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities", "role": "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable", "shortName": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c63", "decimals": "0", "first": true, "lang": null, "name": "biot:InitialMeasurementFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c105", "decimals": "0", "first": true, "lang": null, "name": "biot:AggregateValueEqual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Subsequent Events (Details)", "role": "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c105", "decimals": "0", "first": true, "lang": null, "name": "biot:AggregateValueEqual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c108", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - The Company (Details)", "role": "http://www.biotechacquisitionco.com/role/TheCompanyDetails", "shortName": "The Company (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c108", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c115", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment are stated at cost, subject to adjustments for impairments, less accumulated depreciation and amortization", "role": "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment are stated at cost, subject to adjustments for impairments, less accumulated depreciation and amortization", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c115", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured and recognized at fair value", "role": "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable", "shortName": "Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured and recognized at fair value", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Changes in Shareholders\u2019 (Deficit) Equity (Parentheticals)", "role": "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3_Parentheticals", "shortName": "Consolidated Statements of Changes in Shareholders\u2019 (Deficit) Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "biot:IndemnificationHoldbackBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Fair Value Measurement (Details) - Schedule of changes in the fair value of the indemnification holdback", "role": "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable", "shortName": "Fair Value Measurement (Details) - Schedule of changes in the fair value of the indemnification holdback", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "biot:IndemnificationHoldbackBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfChangesInTheFairValueOfTheContingentConsiderationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "biot:ContingentConsiderationClassifiedAsOperationFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Fair Value Measurement (Details) - Schedule of changes in the fair value of the contingent consideration", "role": "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable", "shortName": "Fair Value Measurement (Details) - Schedule of changes in the fair value of the contingent consideration", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfChangesInTheFairValueOfTheContingentConsiderationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c38", "decimals": "-3", "lang": null, "name": "biot:ContingentConsiderationClassifiedAsOperationFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "biot:FairValueBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Fair Value Measurement (Details) - Schedule of provides the changes in the fair value of the convertible notes", "role": "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable", "shortName": "Fair Value Measurement (Details) - Schedule of provides the changes in the fair value of the convertible notes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "lang": null, "name": "biot:ProceedsAllocatedToCommonStockWarrantsAndTrancheObligationAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c130", "decimals": null, "first": true, "lang": "en-US", "name": "biot:RiskfreeInterestRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Fair Value Measurement (Details) - Schedule of assumptions used for the valuation of the warrants", "role": "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "shortName": "Fair Value Measurement (Details) - Schedule of assumptions used for the valuation of the warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c130", "decimals": null, "first": true, "lang": "en-US", "name": "biot:RiskfreeInterestRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "biot:UnrecognizedZaxBenefitBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Fair Value Measurement (Details) - Schedule of change in fair value of the 2020 and 2021 Warrants", "role": "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable", "shortName": "Fair Value Measurement (Details) - Schedule of change in fair value of the 2020 and 2021 Warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "lang": null, "name": "biot:IssuanceOfWarrant", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Fair Value Measurement (Details) - Schedule of change in fair value of the 2021 Convertible Note tranche obligation", "role": "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable", "shortName": "Fair Value Measurement (Details) - Schedule of change in fair value of the 2021 Convertible Note tranche obligation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Balance Sheet Components (Details)", "role": "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails", "shortName": "Balance Sheet Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Balance Sheet Components (Details) - Schedule of property and equipment, net", "role": "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable", "shortName": "Balance Sheet Components (Details) - Schedule of property and equipment, net", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities", "role": "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable", "shortName": "Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c132", "decimals": "-3", "first": true, "lang": null, "name": "biot:LesseOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Commitments and Contingencies (Details) - Schedule of future minimum facility lease payments", "role": "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable", "shortName": "Commitments and Contingencies (Details) - Schedule of future minimum facility lease payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c132", "decimals": "-3", "first": true, "lang": null, "name": "biot:LesseOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c9", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Income Taxes (Details)", "role": "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Income Taxes (Details) - Schedule of loss before taxes", "role": "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable", "shortName": "Income Taxes (Details) - Schedule of loss before taxes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:SchedulOfProvisionForbenefitFromIncomeTaxesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Income Taxes (Details) - Schedul of provision for income taxes", "role": "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable", "shortName": "Income Taxes (Details) - Schedul of provision for income taxes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:SchedulOfProvisionForbenefitFromIncomeTaxesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets", "role": "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable", "shortName": "Income Taxes (Details) - Schedule of deferred tax assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c143", "decimals": "-5", "first": true, "lang": null, "name": "biot:CertainLoansAcquiredInTransferAccountedForAsAvailableForSaleDebtSecuritiesAcquiredDuringPeriodCashFlowExpectedToBeCollectedAtAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Term Loan Agreement (Details)", "role": "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "shortName": "Term Loan Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c143", "decimals": "-5", "first": true, "lang": null, "name": "biot:CertainLoansAcquiredInTransferAccountedForAsAvailableForSaleDebtSecuritiesAcquiredDuringPeriodCashFlowExpectedToBeCollectedAtAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Term Loan Agreement (Details) - Schedule of future principal payments under the term loan agreement", "role": "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable", "shortName": "Term Loan Agreement (Details) - Schedule of future principal payments under the term loan agreement", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c149", "decimals": "-5", "first": true, "lang": null, "name": "biot:ReceivedProceeds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Convertible Notes (Details)", "role": "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "shortName": "Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c149", "decimals": "-5", "first": true, "lang": null, "name": "biot:ReceivedProceeds", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:ExercisableWarrantsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Common Stock Warrants (Details)", "role": "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "shortName": "Common Stock Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "first": true, "lang": "en-US", "name": "biot:ExercisableWarrantsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c177", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Common Stock Warrants (Details) - Schedule of warrants to purchase shares of the company\u2019s common stock", "role": "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable", "shortName": "Common Stock Warrants (Details) - Schedule of warrants to purchase shares of the company\u2019s common stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c177", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfBlackscholesOptionPricingModel", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c186", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Common Stock Warrants (Details) - Schedule of black-scholes option pricing model", "role": "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "shortName": "Common Stock Warrants (Details) - Schedule of black-scholes option pricing model", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfBlackscholesOptionPricingModel", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c186", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Description of Organization and Business Operations", "role": "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperations", "shortName": "Description of Organization and Business Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "2", "first": true, "lang": null, "name": "biot:ImplementReorganization", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Convertible Preferred Stock (Details)", "role": "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "shortName": "Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "2", "first": true, "lang": null, "name": "biot:ImplementReorganization", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "biot:ConvertiblePreferredStockShareAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Convertible Preferred Stock (Details) - Schedule of convertible preferred stock", "role": "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable", "shortName": "Convertible Preferred Stock (Details) - Schedule of convertible preferred stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "biot:ConvertiblePreferredStockShareAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c10", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentRedemptionPricePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081 - Disclosure - Common Stock (Details)", "role": "http://www.biotechacquisitionco.com/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c10", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentRedemptionPricePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "082 - Disclosure - Common Stock (Details) - Schedule of common stock, on an as-converted basis for issuance", "role": "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable", "shortName": "Common Stock (Details) - Schedule of common stock, on an as-converted basis for issuance", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c8", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c206", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "083 - Disclosure - Stock Option Plan (Details)", "role": "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "shortName": "Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": null, "lang": "en-US", "name": "biot:StockOptionPlanDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "084 - Disclosure - Stock Option Plan (Details) - Schedule of stock option plan exercised option", "role": "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable", "shortName": "Stock Option Plan (Details) - Schedule of stock option plan exercised option", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c210", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c214", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "085 - Disclosure - Stock Option Plan (Details) - Schedule of grant-date fair values of employee and non-employee stock options", "role": "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "shortName": "Stock Option Plan (Details) - Schedule of grant-date fair values of employee and non-employee stock options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c214", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "086 - Disclosure - Stock Option Plan (Details) - Schedule of stock-based compensation expense", "role": "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable", "shortName": "Stock Option Plan (Details) - Schedule of stock-based compensation expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c218", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "087 - Disclosure - License and Research and Development Agreements (Details)", "role": "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails", "shortName": "License and Research and Development Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c218", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c222", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "088 - Disclosure - Acquisition of ATXCo (Details)", "role": "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "shortName": "Acquisition of ATXCo (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c222", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "089 - Disclosure - Net Loss Per Share (Details) - Schedule of basic and diluted loss per share", "role": "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable", "shortName": "Net Loss Per Share (Details) - Schedule of basic and diluted loss per share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "biot:ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c11", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090 - Disclosure - Net Loss Per Share (Details) - Schedule of diluted net loss per share attributable to common stockholders", "role": "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable", "shortName": "Net Loss Per Share (Details) - Schedule of diluted net loss per share attributable to common stockholders", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42022a1_biotechacq.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } } }, "segmentCount": 62, "tag": { "biot_ATXCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ATXCoMember", "terseLabel": "ATXCo [Member]" } } }, "localname": "ATXCoMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "domainItemType" }, "biot_AccountingPoliciesbyPolicyPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies, by Policy (Policies) [Line Items]" } } }, "localname": "AccountingPoliciesbyPolicyPoliciesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "stringItemType" }, "biot_AccountingPoliciesbyPolicyPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies, by Policy (Policies) [Table]" } } }, "localname": "AccountingPoliciesbyPolicyPoliciesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "stringItemType" }, "biot_AccountsPayableRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "AccountsPayableRelatedParty", "terseLabel": "Amounts payable related party" } } }, "localname": "AccountsPayableRelatedParty", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "biot_AccountsPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts payable.", "label": "AccountsPayables", "terseLabel": "Amounts payable" } } }, "localname": "AccountsPayables", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "biot_AccretionOfCarryingValueToRedemptionValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of carrying value to redemption value.", "label": "AccretionOfCarryingValueToRedemptionValue", "terseLabel": "Accretion of carrying value to redemption value" } } }, "localname": "AccretionOfCarryingValueToRedemptionValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "monetaryItemType" }, "biot_AccretionOfCarryingValueToRedemptionValueIPO": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of carrying value to redemption value.", "label": "AccretionOfCarryingValueToRedemptionValueIPO", "terseLabel": "Accretion of carrying value to redemption value \u2013 IPO" } } }, "localname": "AccretionOfCarryingValueToRedemptionValueIPO", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "monetaryItemType" }, "biot_AccruedClinicalStudyCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AccruedClinicalStudyCosts", "terseLabel": "Accrued clinical and research and development costs" } } }, "localname": "AccruedClinicalStudyCosts", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "biot_AcquisitionofATXCoDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition of ATXCo (Details) [Line Items]" } } }, "localname": "AcquisitionofATXCoDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "stringItemType" }, "biot_AcquisitionofATXCoDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition of ATXCo (Details) [Table]" } } }, "localname": "AcquisitionofATXCoDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "stringItemType" }, "biot_AcquisitionofATXCoLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition of ATXCo [Line Items]" } } }, "localname": "AcquisitionofATXCoLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCo" ], "xbrltype": "stringItemType" }, "biot_AcquisitionofATXCoTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition of ATXCo [Table]" } } }, "localname": "AcquisitionofATXCoTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCo" ], "xbrltype": "stringItemType" }, "biot_AdditionalConvertibleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of additional convertible note issued.", "label": "AdditionalConvertibleAmount", "terseLabel": "Additional convertible note amount" } } }, "localname": "AdditionalConvertibleAmount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_AdditionalConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional convertible notes.", "label": "AdditionalConvertibleNotes", "terseLabel": "Additional convertible notes" } } }, "localname": "AdditionalConvertibleNotes", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_AdditionalOfPublicPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional of public per share.", "label": "AdditionalOfPublicPerShare", "terseLabel": "Trust account per share (in Dollars per share)" } } }, "localname": "AdditionalOfPublicPerShare", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "biot_AdditionalSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional shares issued.", "label": "AdditionalSharesIssued", "terseLabel": "Additional shares issued (in Shares)" } } }, "localname": "AdditionalSharesIssued", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "sharesItemType" }, "biot_AdditionalWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional warrants.", "label": "AdditionalWarrants", "terseLabel": "Additional warrants (in Shares)" } } }, "localname": "AdditionalWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "biot_AggregateCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash payment.", "label": "AggregateCashPayment", "terseLabel": "Aggregate cash payment" } } }, "localname": "AggregateCashPayment", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_AggregateGrossProceed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate gross proceed.", "label": "AggregateGrossProceed", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "AggregateGrossProceed", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "biot_AggregateGrossProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate gross proceeds.", "label": "AggregateGrossProceeds", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "AggregateGrossProceeds", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_AggregateIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate issuance.", "label": "AggregateIssuance", "terseLabel": "Aggregate issuance (in Shares)" } } }, "localname": "AggregateIssuance", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "sharesItemType" }, "biot_AggregateOfSharesSoldPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate of shares sold, percentage.", "label": "AggregateOfSharesSoldPercentage", "terseLabel": "Aggregate percentage" } } }, "localname": "AggregateOfSharesSoldPercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "biot_AggregateValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value.", "label": "AggregateValue", "terseLabel": "Aggregate value" } } }, "localname": "AggregateValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_AggregateValueEqual": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate value equal.", "label": "AggregateValueEqual", "terseLabel": "Sponsor agreed prior payments", "verboseLabel": "Aggregate value equal" } } }, "localname": "AggregateValueEqual", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "biot_AssetsAbstract00": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AssetsAbstract00", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract00", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "biot_AssetsAbstract000": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AssetsAbstract000", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract000", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components (Details) [Line Items]" } } }, "localname": "BalanceSheetComponentsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities [Line Items]" } } }, "localname": "BalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities [Table]" } } }, "localname": "BalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components (Details) [Table]" } } }, "localname": "BalanceSheetComponentsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components [Line Items]" } } }, "localname": "BalanceSheetComponentsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponents" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components [Table]" } } }, "localname": "BalanceSheetComponentsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponents" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components (Tables) [Line Items]" } } }, "localname": "BalanceSheetComponentsTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables" ], "xbrltype": "stringItemType" }, "biot_BalanceSheetComponentsTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Components (Tables) [Table]" } } }, "localname": "BalanceSheetComponentsTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables" ], "xbrltype": "stringItemType" }, "biot_BasicAndDilutedNetLossPerOrdinaryShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BasicAndDilutedNetLossPerOrdinaryShareAbstract", "terseLabel": "Basic and diluted net loss per ordinary share" } } }, "localname": "BasicAndDilutedNetLossPerOrdinaryShareAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "stringItemType" }, "biot_BladeTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BladeTherapeuticsIncMember", "terseLabel": "Blade Therapeutics, Inc.", "verboseLabel": "Blade Therapeutics, Inc. [Member]" } } }, "localname": "BladeTherapeuticsIncMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy", "http://www.biotechacquisitionco.com/role/AcquisitionofATXCo", "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/BalanceSheetComponents", "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails", "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables", "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesTables", "http://www.biotechacquisitionco.com/role/CommonStock", "http://www.biotechacquisitionco.com/role/CommonStockDetails", "http://www.biotechacquisitionco.com/role/CommonStockTables", "http://www.biotechacquisitionco.com/role/CommonStockWarrants", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/ConvertibleNotes", "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStock", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockTables", "http://www.biotechacquisitionco.com/role/FairValueMeasurements", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables", "http://www.biotechacquisitionco.com/role/IncomeTaxes", "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails", "http://www.biotechacquisitionco.com/role/IncomeTaxesTables", "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreements", "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails", "http://www.biotechacquisitionco.com/role/NetLossPerShare", "http://www.biotechacquisitionco.com/role/NetLossPerShareTables", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable", "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable", "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable", "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable", "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable", "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable", "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable", "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable", "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable", "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable", "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable", "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable", "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable", "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable", "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/StockOptionPlan", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/StockOptionPlanTables", "http://www.biotechacquisitionco.com/role/SubsequentEvents", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables", "http://www.biotechacquisitionco.com/role/TermLoanAgreement", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementTables", "http://www.biotechacquisitionco.com/role/TheCompany", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "biot_BorrowedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The Value of borrowed amount.", "label": "BorrowedAmount", "terseLabel": "Borrowed amount" } } }, "localname": "BorrowedAmount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "biot_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BusinessCombinationMember", "terseLabel": "Business Combination [Member]" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "biot_BusinessCombinationsStepAcquisitionEquityInterestInAcquireeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination description.", "label": "BusinessCombinationsStepAcquisitionEquityInterestInAcquireeDescription", "terseLabel": "Business combination description" } } }, "localname": "BusinessCombinationsStepAcquisitionEquityInterestInAcquireeDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "biot_CashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash consideration.", "label": "CashConsideration", "terseLabel": "Cash consideration" } } }, "localname": "CashConsideration", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "biot_CertainClinicalMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CertainClinicalMilestoneMember", "terseLabel": "Certain Clinical Milestone [Member]" } } }, "localname": "CertainClinicalMilestoneMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "domainItemType" }, "biot_CertainLoansAcquiredInTransferAccountedForAsAvailableForSaleDebtSecuritiesAcquiredDuringPeriodCashFlowExpectedToBeCollectedAtAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The value of cash tranches.", "label": "CertainLoansAcquiredInTransferAccountedForAsAvailableForSaleDebtSecuritiesAcquiredDuringPeriodCashFlowExpectedToBeCollectedAtAcquisition", "terseLabel": "Cash tranches" } } }, "localname": "CertainLoansAcquiredInTransferAccountedForAsAvailableForSaleDebtSecuritiesAcquiredDuringPeriodCashFlowExpectedToBeCollectedAtAcquisition", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount is change the fair value.", "label": "ChangeInFairValue", "terseLabel": "Change in fair value" } } }, "localname": "ChangeInFairValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInFairValueHoldback": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of change in fair value holdback.", "label": "ChangeInFairValueHoldback", "terseLabel": "Change in fair value" } } }, "localname": "ChangeInFairValueHoldback", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInFairValueMeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "ChangeInFairValueMeasurement", "terseLabel": "Change in fair value" } } }, "localname": "ChangeInFairValueMeasurement", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInFairValueOfContingentConsideration": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of Contingent Consideration.", "label": "ChangeInFairValueOfContingentConsideration", "terseLabel": "Change in fair value of Contingent Consideration" } } }, "localname": "ChangeInFairValueOfContingentConsideration", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInFairValueOfIndemnificationHoldback": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of Indemnification Holdback.", "label": "ChangeInFairValueOfIndemnificationHoldback", "negatedLabel": "Change in fair value of Indemnification Holdback" } } }, "localname": "ChangeInFairValueOfIndemnificationHoldback", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInFairValueOfWarrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of the 2020 and 2021 Warrants", "label": "ChangeInFairValueOfWarrant", "terseLabel": "Change in fair value of the 2020 and 2021 Warrants" } } }, "localname": "ChangeInFairValueOfWarrant", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable" ], "xbrltype": "monetaryItemType" }, "biot_ChangeInValueOfCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in value of common stock subject to possible redemption.", "label": "ChangeInValueOfCommonStockSubjectToPossibleRedemption", "terseLabel": "Initial classification of Class A ordinary shares subject to possible redemption" } } }, "localname": "ChangeInValueOfCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock", "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption" } } }, "localname": "ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_CombinationPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Combination price per share.", "label": "CombinationPricePerShare", "terseLabel": "Combination price per share (in Dollars per share)" } } }, "localname": "CombinationPricePerShare", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "biot_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesDetailsScheduleoffutureminimumfacilityleasepaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of future minimum facility lease payments [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleoffutureminimumfacilityleasepaymentsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesDetailsScheduleoffutureminimumfacilityleasepaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of future minimum facility lease payments [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleoffutureminimumfacilityleasepaymentsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]" } } }, "localname": "CommitmentsandContingenciesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Table]" } } }, "localname": "CommitmentsandContingenciesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Tables) [Line Items]" } } }, "localname": "CommitmentsandContingenciesTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "stringItemType" }, "biot_CommitmentsandContingenciesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Tables) [Table]" } } }, "localname": "CommitmentsandContingenciesTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "stringItemType" }, "biot_CommonStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) [Line Items]" } } }, "localname": "CommonStockDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "biot_CommonStockDetailsScheduleofcommonstockonanasconvertedbasisforissuanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) - Schedule of common stock, on an as-converted basis for issuance [Line Items]" } } }, "localname": "CommonStockDetailsScheduleofcommonstockonanasconvertedbasisforissuanceLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable" ], "xbrltype": "stringItemType" }, "biot_CommonStockDetailsScheduleofcommonstockonanasconvertedbasisforissuanceTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) - Schedule of common stock, on an as-converted basis for issuance [Table]" } } }, "localname": "CommonStockDetailsScheduleofcommonstockonanasconvertedbasisforissuanceTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable" ], "xbrltype": "stringItemType" }, "biot_CommonStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) [Table]" } } }, "localname": "CommonStockDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "biot_CommonStockEquityRaise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CommonStockEquityRaise", "terseLabel": "Equity raise" } } }, "localname": "CommonStockEquityRaise", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_CommonStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Line Items]" } } }, "localname": "CommonStockLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStock" ], "xbrltype": "stringItemType" }, "biot_CommonStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock outstanding, percentage.", "label": "CommonStockOutstandingPercentage", "terseLabel": "Converted basis, percentage" } } }, "localname": "CommonStockOutstandingPercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "percentItemType" }, "biot_CommonStockParOrStatedValuePerShare1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "CommonStockParOrStatedValuePerShare1", "terseLabel": "Ordinary shares, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare1", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "perShareItemType" }, "biot_CommonStockParOrStatedValuesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Par or Stated Value Per Share.", "label": "CommonStockParOrStatedValuesPerShare", "terseLabel": "Per share (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuesPerShare", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "biot_CommonStockSharesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockSharesPercent", "terseLabel": "Percent of common stock shares" } } }, "localname": "CommonStockSharesPercent", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "percentItemType" }, "biot_CommonStockTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Table]" } } }, "localname": "CommonStockTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStock" ], "xbrltype": "stringItemType" }, "biot_CommonStockTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Tables) [Line Items]" } } }, "localname": "CommonStockTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockTables" ], "xbrltype": "stringItemType" }, "biot_CommonStockTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Tables) [Table]" } } }, "localname": "CommonStockTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockTables" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock warrant liability.", "label": "CommonStockWarrantLiability", "terseLabel": "Common stock warrant liability" } } }, "localname": "CommonStockWarrantLiability", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "biot_CommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockWarrants", "terseLabel": "Common Stock Warrants" } } }, "localname": "CommonStockWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrants" ], "xbrltype": "textBlockItemType" }, "biot_CommonStockWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Abstract]" } } }, "localname": "CommonStockWarrantsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants (Details) [Line Items]" } } }, "localname": "CommonStockWarrantsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsDetailsScheduleofblackscholesoptionpricingmodelLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants (Details) - Schedule of black-scholes option pricing model [Line Items]" } } }, "localname": "CommonStockWarrantsDetailsScheduleofblackscholesoptionpricingmodelLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsDetailsScheduleofblackscholesoptionpricingmodelTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants (Details) - Schedule of black-scholes option pricing model [Table]" } } }, "localname": "CommonStockWarrantsDetailsScheduleofblackscholesoptionpricingmodelTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants (Details) [Table]" } } }, "localname": "CommonStockWarrantsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Line Items]" } } }, "localname": "CommonStockWarrantsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrants" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Table]" } } }, "localname": "CommonStockWarrantsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrants" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants (Tables) [Line Items]" } } }, "localname": "CommonStockWarrantsTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables" ], "xbrltype": "stringItemType" }, "biot_CommonStockWarrantsTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants (Tables) [Table]" } } }, "localname": "CommonStockWarrantsTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables" ], "xbrltype": "stringItemType" }, "biot_CommonStocksValue": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stocks value.", "label": "CommonStocksValue", "terseLabel": "Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 5,750,000 shares issued and outstanding, at December 31, 2021 and 2020" } } }, "localname": "CommonStocksValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "biot_ConcentrationOfCreditRiskAndOffbalanceSheetRiskPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConcentrationOfCreditRiskAndOffbalanceSheetRiskPolicyTextBlock", "terseLabel": "Concentration of Credit Risk and Off-balance Sheet Risk" } } }, "localname": "ConcentrationOfCreditRiskAndOffbalanceSheetRiskPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_ContingentConsiderationClassifiedAsOperationFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in a business combination that is classified in operation.", "label": "ContingentConsiderationClassifiedAsOperationFairValueDisclosure", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContingentConsiderationClassifiedAsOperationFairValueDisclosure", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable" ], "xbrltype": "monetaryItemType" }, "biot_ConversionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConversionPricePercentage", "terseLabel": "Conversion price rate" } } }, "localname": "ConversionPricePercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "biot_ConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertibleNoteMember", "terseLabel": "2020 Convertible Notes [Member]" } } }, "localname": "ConvertibleNoteMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_ConvertibleNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "ConvertibleNotePayable", "terseLabel": "Convertible promissory notes" } } }, "localname": "ConvertibleNotePayable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "biot_ConvertibleNoteTrancheObligationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertibleNoteTrancheObligationPolicyTextBlock", "terseLabel": "Convertible Note Tranche Obligation" } } }, "localname": "ConvertibleNoteTrancheObligationPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_ConvertibleNotesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes (Details) [Line Items]" } } }, "localname": "ConvertibleNotesDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "biot_ConvertibleNotesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes (Details) [Table]" } } }, "localname": "ConvertibleNotesDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "biot_ConvertibleNotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes [Line Items]" } } }, "localname": "ConvertibleNotesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotes" ], "xbrltype": "stringItemType" }, "biot_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertibleNotesMember", "terseLabel": "2021 Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_ConvertibleNotesPayableIssuanceCostsInAccountsPayableAndAccruals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable issuance costs in accounts payable and accruals.", "label": "ConvertibleNotesPayableIssuanceCostsInAccountsPayableAndAccruals", "terseLabel": "Convertible notes payable issuance costs in accounts payable and accruals" } } }, "localname": "ConvertibleNotesPayableIssuanceCostsInAccountsPayableAndAccruals", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_ConvertibleNotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes [Table]" } } }, "localname": "ConvertibleNotesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotes" ], "xbrltype": "stringItemType" }, "biot_ConvertibleNotesdescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible notes,description.", "label": "ConvertibleNotesdescription", "terseLabel": "Convertible notes, description" } } }, "localname": "ConvertibleNotesdescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Details) [Line Items]" } } }, "localname": "ConvertiblePreferredStockDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Details) [Table]" } } }, "localname": "ConvertiblePreferredStockDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Line Items]" } } }, "localname": "ConvertiblePreferredStockLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockProceedsNetIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Proceeds, Net Issuance Cost.", "label": "ConvertiblePreferredStockProceedsNetIssuanceCost", "terseLabel": "Convertible Preferred Stock, Proceeds, Net Issuance Cost" } } }, "localname": "ConvertiblePreferredStockProceedsNetIssuanceCost", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "monetaryItemType" }, "biot_ConvertiblePreferredStockSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePreferredStockSeriesAMember", "terseLabel": "Series A [Member]", "verboseLabel": "Convertible Preferred Stock Series A [Member]" } } }, "localname": "ConvertiblePreferredStockSeriesAMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "domainItemType" }, "biot_ConvertiblePreferredStockSeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePreferredStockSeriesBMember", "terseLabel": "Series B [Member]", "verboseLabel": "Convertible Preferred Stock Series B [Member]" } } }, "localname": "ConvertiblePreferredStockSeriesBMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "domainItemType" }, "biot_ConvertiblePreferredStockSeriesCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePreferredStockSeriesCMember", "terseLabel": "Series C [Member]", "verboseLabel": "Convertible Preferred Stock Series C [Member]" } } }, "localname": "ConvertiblePreferredStockSeriesCMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "domainItemType" }, "biot_ConvertiblePreferredStockShareAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Shares Authorized.", "label": "ConvertiblePreferredStockShareAuthorized", "terseLabel": "Convertible Preferred Stock, Shares Authorized" } } }, "localname": "ConvertiblePreferredStockShareAuthorized", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "sharesItemType" }, "biot_ConvertiblePreferredStockTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Table]" } } }, "localname": "ConvertiblePreferredStockTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Tables) [Line Items]" } } }, "localname": "ConvertiblePreferredStockTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Tables) [Table]" } } }, "localname": "ConvertiblePreferredStockTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "stringItemType" }, "biot_ConvertiblePreferredStockValue": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock value.", "label": "ConvertiblePreferredStockValue", "terseLabel": "Convertible preferred stock, $0.0001 par value, 133,656,880 and 151,185,364 shares authorized at December 31, 2020 and 2021, respectively; 83,044,690 shares issued and outstanding at December 31, 2020 and 2021 (aggregate liquidation preference of $90,365 at December 31, 2021)" } } }, "localname": "ConvertiblePreferredStockValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "biot_ConvertiblePreferredStocksShareOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Shares Outstanding.", "label": "ConvertiblePreferredStocksShareOutstanding", "terseLabel": "Convertible Preferred Stock, Shares Outstanding" } } }, "localname": "ConvertiblePreferredStocksShareOutstanding", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "sharesItemType" }, "biot_ConvertiblePromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes.", "label": "ConvertiblePromissoryNotes", "terseLabel": "Convertible promissory notes" } } }, "localname": "ConvertiblePromissoryNotes", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "biot_ConvertiblesNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblesNoteMember", "terseLabel": "2015 Convertible Note [Member]" } } }, "localname": "ConvertiblesNoteMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_CurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CurrentAbstract", "terseLabel": "Current:" } } }, "localname": "CurrentAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "biot_DeferredRentCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DeferredRentCurrentPortion", "terseLabel": "Deferred rent, current portion" } } }, "localname": "DeferredRentCurrentPortion", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "biot_DeferredRevenueArrangementType_Domain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeferredRevenueArrangementType_ [Domain]" } } }, "localname": "DeferredRevenueArrangementType_Domain", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "biot_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeferredTaxAssetsAbstract", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "biot_DeferredTransactionCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeferredTransactionCosts", "terseLabel": "Deferred Transaction Costs" } } }, "localname": "DeferredTransactionCosts", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_DeferredUnderwritersDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriters discount.", "label": "DeferredUnderwritersDiscount", "terseLabel": "Deferred underwriters discount" } } }, "localname": "DeferredUnderwritersDiscount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "biot_DeferredUnderwritingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fees.", "label": "DeferredUnderwritingFees", "terseLabel": "Deferred underwriting fees" } } }, "localname": "DeferredUnderwritingFees", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DenominatorAbstract", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "stringItemType" }, "biot_DenominatorAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DenominatorAbstract0", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract0", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "stringItemType" }, "biot_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations (Details) [Line Items]" } } }, "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "biot_DescriptionofOrganizationandBusinessOperationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations (Details) [Table]" } } }, "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "biot_DeterminedFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DeterminedFairValue", "terseLabel": "Issuance of fair value" } } }, "localname": "DeterminedFairValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_DeterminedFairValue1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DeterminedFairValue1", "terseLabel": "Determined fair value" } } }, "localname": "DeterminedFairValue1", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_DueAfterTheDateOfFinancialStatementsIssuedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due after the date of financial statements issued.", "label": "DueAfterTheDateOfFinancialStatementsIssuedTerm", "terseLabel": "Due after the date of financial statements issued" } } }, "localname": "DueAfterTheDateOfFinancialStatementsIssuedTerm", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "durationItemType" }, "biot_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EmergingGrowthCompanyPolicyTextBlock", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EmergingGrowthCompanyStatusPolicyTextBlock", "terseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_EquityClassifiedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EquityClassifiedAbstract", "terseLabel": "Equity-classified" } } }, "localname": "EquityClassifiedAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "stringItemType" }, "biot_EstimatedFairValueOfThePublicWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated fair value of the public warrants.", "label": "EstimatedFairValueOfThePublicWarrants", "terseLabel": "Estimated fair value of the public warrants" } } }, "localname": "EstimatedFairValueOfThePublicWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_ExercisableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercisable term.", "label": "ExercisableTerm", "terseLabel": "Exercisable term" } } }, "localname": "ExercisableTerm", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "durationItemType" }, "biot_ExercisableWarrantsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercisable warrants description.", "label": "ExercisableWarrantsDescription", "terseLabel": "Exercisable warrants description" } } }, "localname": "ExercisableWarrantsDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "biot_ExpensedOfIssuanceCostsIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "ExpensedOfIssuanceCostsIncurred", "terseLabel": "Expensed of issuance costs incurred" } } }, "localname": "ExpensedOfIssuanceCostsIncurred", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_ExpireYear": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExpireYear", "terseLabel": "Expire year" } } }, "localname": "ExpireYear", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "biot_ExtinguishmentOfTrancheObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Extinguishment of tranche obligation", "label": "ExtinguishmentOfTrancheObligation", "terseLabel": "Extinguishment of tranche obligation" } } }, "localname": "ExtinguishmentOfTrancheObligation", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable" ], "xbrltype": "monetaryItemType" }, "biot_FairValueAdjustmentOfWarrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value Adjustment of Warrants", "label": "FairValueAdjustmentOfWarrant", "terseLabel": "Fair value adjustment of warrants" } } }, "localname": "FairValueAdjustmentOfWarrant", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_FairValueBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "FairValueBalance", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueBalance", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "biot_FairValueMeasurementDetailsScheduleofassumptionsusedforthevaluationofthewarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of assumptions used for the valuation of the warrants [Line Items]" } } }, "localname": "FairValueMeasurementDetailsScheduleofassumptionsusedforthevaluationofthewarrantsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofassumptionsusedforthevaluationofthewarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of assumptions used for the valuation of the warrants [Table]" } } }, "localname": "FairValueMeasurementDetailsScheduleofassumptionsusedforthevaluationofthewarrantsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofchangeinfairvalueofthe2020and2021WarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of change in fair value of the 2020 and 2021 Warrants [Line Items]" } } }, "localname": "FairValueMeasurementDetailsScheduleofchangeinfairvalueofthe2020and2021WarrantsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofchangeinfairvalueofthe2020and2021WarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of change in fair value of the 2020 and 2021 Warrants [Table]" } } }, "localname": "FairValueMeasurementDetailsScheduleofchangeinfairvalueofthe2020and2021WarrantsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofchangesinthefairvalueofthecontingentconsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of changes in the fair value of the contingent consideration [Line Items]" } } }, "localname": "FairValueMeasurementDetailsScheduleofchangesinthefairvalueofthecontingentconsiderationLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofchangesinthefairvalueofthecontingentconsiderationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of changes in the fair value of the contingent consideration [Table]" } } }, "localname": "FairValueMeasurementDetailsScheduleofchangesinthefairvalueofthecontingentconsiderationTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofchangesinthefairvalueoftheindemnificationholdbackLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of changes in the fair value of the indemnification holdback [Line Items]" } } }, "localname": "FairValueMeasurementDetailsScheduleofchangesinthefairvalueoftheindemnificationholdbackLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofchangesinthefairvalueoftheindemnificationholdbackTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of changes in the fair value of the indemnification holdback [Table]" } } }, "localname": "FairValueMeasurementDetailsScheduleofchangesinthefairvalueoftheindemnificationholdbackTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured and recognized at fair value [Line Items]" } } }, "localname": "FairValueMeasurementDetailsScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured and recognized at fair value [Table]" } } }, "localname": "FairValueMeasurementDetailsScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of provides the changes in the fair value of the convertible notes [Line Items]" } } }, "localname": "FairValueMeasurementDetailsScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementDetailsScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement (Details) - Schedule of provides the changes in the fair value of the convertible notes [Table]" } } }, "localname": "FairValueMeasurementDetailsScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsDetailsScheduleofassetsthataremeasuredatfairvalueonarecurringbasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of assets that are measured at fair value on a recurring basis [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofassetsthataremeasuredatfairvalueonarecurringbasisLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsDetailsScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of assets that are measured at fair value on a recurring basis [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) [Table]" } } }, "localname": "FairValueMeasurementsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements [Line Items]" } } }, "localname": "FairValueMeasurementsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurements" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements [Table]" } } }, "localname": "FairValueMeasurementsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurements" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Tables) [Line Items]" } } }, "localname": "FairValueMeasurementsTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "biot_FairValueMeasurementsTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Tables) [Table]" } } }, "localname": "FairValueMeasurementsTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "biot_FairValueOfIndemnificationHoldback": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of indemnification holdback.", "label": "FairValueOfIndemnificationHoldback", "terseLabel": "Fair value of indemnification holdback" } } }, "localname": "FairValueOfIndemnificationHoldback", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "biot_FairValueOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of shares.", "label": "FairValueOfShares", "terseLabel": "Fair value of shares" } } }, "localname": "FairValueOfShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "biot_FairValueOfTheInitialWarrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the initial warrant.", "label": "FairValueOfTheInitialWarrant", "terseLabel": "Fair value of the initial warrant" } } }, "localname": "FairValueOfTheInitialWarrant", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "biot_FairValueOfTheWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the warrants.", "label": "FairValueOfTheWarrants", "terseLabel": "Fair value of warrants" } } }, "localname": "FairValueOfTheWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "biot_FounderShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares.", "label": "FounderShares", "terseLabel": "Founder shares (in Shares)" } } }, "localname": "FounderShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "biot_GrossProceed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate gross proceeds.", "label": "GrossProceed", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "GrossProceed", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "biot_GrossProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds.", "label": "GrossProceeds", "terseLabel": "Gross proceeds" } } }, "localname": "GrossProceeds", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_HealthCareOrganizationRevenueSources_Domain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HealthCareOrganizationRevenueSources_ [Domain]" } } }, "localname": "HealthCareOrganizationRevenueSources_Domain", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "domainItemType" }, "biot_ImplementReorganization": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ImplementReorganization", "terseLabel": "Implement reorganization of voting power, percentage" } } }, "localname": "ImplementReorganization", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "biot_IncomeTaxesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IncomeTaxesDescription", "terseLabel": "Income taxes, description" } } }, "localname": "IncomeTaxesDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of deferred tax assets [Line Items]" } } }, "localname": "IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of deferred tax assets [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofdeferredtaxassetsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsScheduleoflossbeforetaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of loss before taxes [Line Items]" } } }, "localname": "IncomeTaxesDetailsScheduleoflossbeforetaxesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsScheduleoflossbeforetaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of loss before taxes [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleoflossbeforetaxesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsSchedulofprovisionforincometaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedul of provision for income taxes [Line Items]" } } }, "localname": "IncomeTaxesDetailsSchedulofprovisionforincometaxesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsSchedulofprovisionforincometaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedul of provision for income taxes [Table]" } } }, "localname": "IncomeTaxesDetailsSchedulofprovisionforincometaxesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Tables) [Line Items]" } } }, "localname": "IncomeTaxesTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "biot_IncomeTaxesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Tables) [Table]" } } }, "localname": "IncomeTaxesTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "biot_Indebtedness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Indebtedness.", "label": "Indebtedness", "terseLabel": "Indebtedness" } } }, "localname": "Indebtedness", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "biot_IndemnificationHoldbackBeginningBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of indemnification holdback.", "label": "IndemnificationHoldbackBeginningBalance", "periodEndLabel": "Indemnification holdback, ending balance", "periodStartLabel": "Indemnification holdback, beginning balance" } } }, "localname": "IndemnificationHoldbackBeginningBalance", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable" ], "xbrltype": "monetaryItemType" }, "biot_InitialBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial business combination.", "label": "InitialBusinessCombination", "terseLabel": "Initial business combination" } } }, "localname": "InitialBusinessCombination", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "biot_InitialClassificationOfPrivateWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial classification of private warrant liability.", "label": "InitialClassificationOfPrivateWarrantLiability", "negatedLabel": "Initial classification of private warrant liability" } } }, "localname": "InitialClassificationOfPrivateWarrantLiability", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_InitialClassificationOfPublicWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial classification of public warrant liability.", "label": "InitialClassificationOfPublicWarrantLiability", "negatedLabel": "Initial classification of public warrant liability" } } }, "localname": "InitialClassificationOfPublicWarrantLiability", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_InitialMeasurementFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "InitialMeasurementFairValue", "terseLabel": "Initial measurement on January 28, 2021" } } }, "localname": "InitialMeasurementFairValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "biot_InitialPublicOfferingDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering, description.", "label": "InitialPublicOfferingDescription", "terseLabel": "Initial public offering, description" } } }, "localname": "InitialPublicOfferingDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "biot_InitialPublicOfferingDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Line Items]" } } }, "localname": "InitialPublicOfferingDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "biot_InitialPublicOfferingDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Table]" } } }, "localname": "InitialPublicOfferingDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "biot_InitialPublicOfferingDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering Disclosure [Abstract]" } } }, "localname": "InitialPublicOfferingDisclosureAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_InitialPublicOfferingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Disclosure Text Block.", "label": "InitialPublicOfferingDisclosureTextBlock", "terseLabel": "INITIAL PUBLIC OFFERING" } } }, "localname": "InitialPublicOfferingDisclosureTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "biot_InitialStockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "InitialStockholdersMember", "terseLabel": "Founders [Member]" } } }, "localname": "InitialStockholdersMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "biot_IssuanceCostsRelatedToEquityAndDebtPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuanceCostsRelatedToEquityAndDebtPolicyTextBlock", "terseLabel": "Issuance Costs Related to Equity and Debt" } } }, "localname": "IssuanceCostsRelatedToEquityAndDebtPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_IssuanceOfChangeInFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "IssuanceOfChangeInFairValue", "terseLabel": "Issuance of change in fair value" } } }, "localname": "IssuanceOfChangeInFairValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_IssuanceOfChangeInFairValue1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of change in fair value.", "label": "IssuanceOfChangeInFairValue1", "terseLabel": "Issuance of change in fair value" } } }, "localname": "IssuanceOfChangeInFairValue1", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_IssuanceOfSeriesC1PreferredStockToSettleIndemnificationHoldback": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of Series C-1 preferred stock to settle Indemnification Holdback", "label": "IssuanceOfSeriesC1PreferredStockToSettleIndemnificationHoldback", "terseLabel": "Issuance of Series C-1 preferred stock to settle Indemnification Holdback" } } }, "localname": "IssuanceOfSeriesC1PreferredStockToSettleIndemnificationHoldback", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "biot_IssuanceOfSeriesC1PreferredStockToSettleIndemnificationHoldbackinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Series C-1 preferred stock to settle Indemnification Holdback (in Shares)", "label": "IssuanceOfSeriesC1PreferredStockToSettleIndemnificationHoldbackinShares", "terseLabel": "Issuance of Series C-1 preferred stock to settle Indemnification Holdback (in Shares)" } } }, "localname": "IssuanceOfSeriesC1PreferredStockToSettleIndemnificationHoldbackinShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "biot_IssuanceOfWarrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of warrants", "label": "IssuanceOfWarrant", "terseLabel": "Issuance of warrants" } } }, "localname": "IssuanceOfWarrant", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable" ], "xbrltype": "monetaryItemType" }, "biot_IssuedAndOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and outstanding shares.", "label": "IssuedAndOutstandingShares", "terseLabel": "Issued and outstanding shares, percentage" } } }, "localname": "IssuedAndOutstandingShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "biot_IssuedOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued outstanding percentage.", "label": "IssuedOutstandingPercentage", "terseLabel": "Percentage of issued and outstanding shares" } } }, "localname": "IssuedOutstandingPercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "biot_LabEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "LabEquipment", "terseLabel": "Lab equipment" } } }, "localname": "LabEquipment", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "biot_LegalExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Legal expenses.", "label": "LegalExpenses", "terseLabel": "Legal expenses" } } }, "localname": "LegalExpenses", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "biot_LessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LessAbstract", "terseLabel": "Less:" } } }, "localname": "LessAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "stringItemType" }, "biot_LesseOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total minimum lease payments.", "label": "LesseOperatingLeaseLiabilityPaymentsDue", "negatedLabel": "Total minimum lease payments" } } }, "localname": "LesseOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "biot_LesseOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "LesseOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "negatedLabel": "2022" } } }, "localname": "LesseOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "biot_LiabilitiesAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LiabilitiesAbstract0", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract0", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "stringItemType" }, "biot_LiabilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LiabilityAxis", "terseLabel": "Liability [Axis]" } } }, "localname": "LiabilityAxis", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "stringItemType" }, "biot_LiabilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability [Domain]" } } }, "localname": "LiabilityDomain", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_LiabilityForEarlyExerciseOfStockOptionsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability for Early Exercise of Stock Options , Description.", "label": "LiabilityForEarlyExerciseOfStockOptionsDescription", "terseLabel": "Liability for early exercise of stock options , description" } } }, "localname": "LiabilityForEarlyExerciseOfStockOptionsDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "biot_LicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "LicenseAgreement", "terseLabel": "License agreement" } } }, "localname": "LicenseAgreement", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "durationItemType" }, "biot_LicenseandResearchandDevelopmentAgreementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License and Research and Development Agreements (Details) [Line Items]" } } }, "localname": "LicenseandResearchandDevelopmentAgreementsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "stringItemType" }, "biot_LicenseandResearchandDevelopmentAgreementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License and Research and Development Agreements (Details) [Table]" } } }, "localname": "LicenseandResearchandDevelopmentAgreementsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "stringItemType" }, "biot_LicenseandResearchandDevelopmentAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License and Research and Development Agreements [Line Items]" } } }, "localname": "LicenseandResearchandDevelopmentAgreementsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreements" ], "xbrltype": "stringItemType" }, "biot_LicenseandResearchandDevelopmentAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License and Research and Development Agreements [Table]" } } }, "localname": "LicenseandResearchandDevelopmentAgreementsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreements" ], "xbrltype": "stringItemType" }, "biot_LiquidityAndGoingConcernMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LiquidityAndGoingConcernMember", "terseLabel": "Liquidity and Going Concern [Member]" } } }, "localname": "LiquidityAndGoingConcernMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "biot_MarketPriceOfPublicShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MarketPriceOfPublicShares", "terseLabel": "Market price of public shares" } } }, "localname": "MarketPriceOfPublicShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "perShareItemType" }, "biot_MaximumNetInterestToPayDissolutionExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum net interest to pay dissolution expenses.", "label": "MaximumNetInterestToPayDissolutionExpenses", "terseLabel": "Dissolution expenses" } } }, "localname": "MaximumNetInterestToPayDissolutionExpenses", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_NegativeCashFlowsFromOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of negative cash flows from operations.", "label": "NegativeCashFlowsFromOperations", "terseLabel": "Negative cash flows from operations" } } }, "localname": "NegativeCashFlowsFromOperations", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "biot_NetLossAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares; of income (loss) available to common shareholders.", "label": "NetLossAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare", "totalLabel": "Net loss attributable to common stockholders, basic and diluted" } } }, "localname": "NetLossAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "biot_NetLossPerShareAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares.", "label": "NetLossPerShareAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)" } } }, "localname": "NetLossPerShareAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "biot_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net loss per share attributable to common stockholders, basic and diluted.", "label": "NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "perShareItemType" }, "biot_NetLossPerShareDetailsScheduleofbasicanddilutedlosspershareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Details) - Schedule of basic and diluted loss per share [Line Items]" } } }, "localname": "NetLossPerShareDetailsScheduleofbasicanddilutedlosspershareLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "stringItemType" }, "biot_NetLossPerShareDetailsScheduleofbasicanddilutedlosspershareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Details) - Schedule of basic and diluted loss per share [Table]" } } }, "localname": "NetLossPerShareDetailsScheduleofbasicanddilutedlosspershareTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "stringItemType" }, "biot_NetLossPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share [Line Items]" } } }, "localname": "NetLossPerShareLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShare" ], "xbrltype": "stringItemType" }, "biot_NetLossPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share [Table]" } } }, "localname": "NetLossPerShareTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShare" ], "xbrltype": "stringItemType" }, "biot_NetLossPerShareTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Tables) [Line Items]" } } }, "localname": "NetLossPerShareTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShareTables" ], "xbrltype": "stringItemType" }, "biot_NetLossPerShareTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Tables) [Table]" } } }, "localname": "NetLossPerShareTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShareTables" ], "xbrltype": "stringItemType" }, "biot_NetOperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NetOperatingLeaseMember", "terseLabel": "Net Operating Lease [Member]" } } }, "localname": "NetOperatingLeaseMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "domainItemType" }, "biot_NetOperatingLossesRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NetOperatingLossesRate", "terseLabel": "Rate of net operating losses" } } }, "localname": "NetOperatingLossesRate", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "biot_NetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net tangible assets.", "label": "NetTangibleAssets", "terseLabel": "Net tangible assets" } } }, "localname": "NetTangibleAssets", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_Netlosspersharecommonstockholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Total value of net loss per shre common stockholders.", "label": "Netlosspersharecommonstockholders", "terseLabel": "Total" } } }, "localname": "Netlosspersharecommonstockholders", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "biot_NonfoundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NonfoundingMember", "terseLabel": "Non-founding [Member]" } } }, "localname": "NonfoundingMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "biot_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumeratorAbstract", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "stringItemType" }, "biot_NumeratorAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumeratorAbstract0", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract0", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "stringItemType" }, "biot_OfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OfferingCostsPolicyTextBlock", "terseLabel": "Offering Costs" } } }, "localname": "OfferingCostsPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_OfferingCostsRelatedToWarrantLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs related to warrant liabilities.", "label": "OfferingCostsRelatedToWarrantLiabilities", "terseLabel": "Offering costs related to warrant liabilities" } } }, "localname": "OfferingCostsRelatedToWarrantLiabilities", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "biot_OfferingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering price per share.", "label": "OfferingPricePerShare", "terseLabel": "Offering price per share (in Dollars per share)" } } }, "localname": "OfferingPricePerShare", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "biot_OnetouchHurdle": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One-touch hurdle.", "label": "OnetouchHurdle", "terseLabel": "One-touch hurdle" } } }, "localname": "OnetouchHurdle", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "perShareItemType" }, "biot_OperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OperatingLeaseMember", "terseLabel": "Operating Lease [Member]" } } }, "localname": "OperatingLeaseMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "domainItemType" }, "biot_OrdinarySharesIssuedOutstandingDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares issued outstanding description.", "label": "OrdinarySharesIssuedOutstandingDescription", "terseLabel": "Ordinary shares issued and outstanding description" } } }, "localname": "OrdinarySharesIssuedOutstandingDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "stringItemType" }, "biot_OrdinarySharesSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares subject to possible redemption.", "label": "OrdinarySharesSubjectToPossibleRedemption", "terseLabel": "Ordinary shares subject to possible redemption" } } }, "localname": "OrdinarySharesSubjectToPossibleRedemption", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "biot_OtherAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OtherAccruedExpenses", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedExpenses", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "biot_OtherOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "OtherOfferingCosts", "terseLabel": "Other offering costs" } } }, "localname": "OtherOfferingCosts", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_OutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of convertible outstanding amount.", "label": "OutstandingAmount", "terseLabel": "Outstanding amount" } } }, "localname": "OutstandingAmount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_OutstandingPublicSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding public shares, percentage.", "label": "OutstandingPublicSharesPercentage", "terseLabel": "Outstanding public shares, percentage" } } }, "localname": "OutstandingPublicSharesPercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "biot_OutstandingVotingSecuritiesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding voting securities, percentage.", "label": "OutstandingVotingSecuritiesPercentage", "terseLabel": "Outstanding voting securities, percentage" } } }, "localname": "OutstandingVotingSecuritiesPercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "biot_PaymentOfFormationCostsThroughIssuanceOfClassBOrdinaryShares": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentOfFormationCostsThroughIssuanceOfClassBOrdinaryShares", "negatedLabel": "Payment of formation costs through issuance of Class B ordinary shares" } } }, "localname": "PaymentOfFormationCostsThroughIssuanceOfClassBOrdinaryShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_PaymentOfIndemnificationHoldback": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of Indemnification Holdback.", "label": "PaymentOfIndemnificationHoldback", "negatedLabel": "Payment of Indemnification Holdback" } } }, "localname": "PaymentOfIndemnificationHoldback", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_PaymentOfQualifyingIndemnificationExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of payment of qualifying indemnification expenses.", "label": "PaymentOfQualifyingIndemnificationExpenses", "terseLabel": "Payment of qualifying indemnification expenses" } } }, "localname": "PaymentOfQualifyingIndemnificationExpenses", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable" ], "xbrltype": "monetaryItemType" }, "biot_PercentageHeldInTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage held in trust account.", "label": "PercentageHeldInTrustAccount", "terseLabel": "Assets held in the trust account, percentage" } } }, "localname": "PercentageHeldInTrustAccount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "biot_PercentageOfLiquidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of liquidation", "label": "PercentageOfLiquidation", "terseLabel": "Percentage of liquidation" } } }, "localname": "PercentageOfLiquidation", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "biot_PlacementAgentFeesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement Agent Fees, Description.", "label": "PlacementAgentFeesDescription", "terseLabel": "Placement agent fees, description" } } }, "localname": "PlacementAgentFeesDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "biot_PlusAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PlusAbstract", "terseLabel": "Plus:" } } }, "localname": "PlusAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "stringItemType" }, "biot_PreferenceSharesIssuedOrOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preference shares issued or outstanding description.", "label": "PreferenceSharesIssuedOrOutstanding", "terseLabel": "Preference shares issued or outstanding description" } } }, "localname": "PreferenceSharesIssuedOrOutstanding", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "stringItemType" }, "biot_PrivatePlacementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement [Abstract]" } } }, "localname": "PrivatePlacementAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_PrivatePlacementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Line Items]" } } }, "localname": "PrivatePlacementDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "biot_PrivatePlacementDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Table]" } } }, "localname": "PrivatePlacementDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "biot_PrivatePlacementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PrivatePlacementTextBlock", "terseLabel": "PRIVATE PLACEMENT" } } }, "localname": "PrivatePlacementTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "biot_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PrivatePlacementWarrantsMember", "terseLabel": "(Initial Measurement) Private Warrants [Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "domainItemType" }, "biot_PrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PrivateWarrantsMember", "terseLabel": "Private Warrants [Member]" } } }, "localname": "PrivateWarrantsMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "domainItemType" }, "biot_ProceedsAllocatedToCommonStockWarrantsAndTrancheObligationAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds allocated to 2021 common stock warrants and tranche obligation at fair value.", "label": "ProceedsAllocatedToCommonStockWarrantsAndTrancheObligationAtFairValue", "terseLabel": "Proceeds allocated to 2021 common stock warrants and tranche obligation at fair value" } } }, "localname": "ProceedsAllocatedToCommonStockWarrantsAndTrancheObligationAtFairValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "biot_ProceedsAllocatedToCommonStockWarrantsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds allocated to 2020 common stock warrants at fair value\r \n.", "label": "ProceedsAllocatedToCommonStockWarrantsAtFairValue", "terseLabel": "Proceeds allocated to 2020 common stock warrants at fair value" } } }, "localname": "ProceedsAllocatedToCommonStockWarrantsAtFairValue", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "biot_ProceedsFromIssuanceConvertibleNotesAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance 2020 convertible notes and warrants\r \n.", "label": "ProceedsFromIssuanceConvertibleNotesAndWarrants", "terseLabel": "Proceeds from issuance 2020 convertible notes and warrants" } } }, "localname": "ProceedsFromIssuanceConvertibleNotesAndWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "biot_ProcessResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ProcessResearchAndDevelopment", "terseLabel": "Research and development" } } }, "localname": "ProcessResearchAndDevelopment", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "biot_PromissoryBalanceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Promissory balance amount.", "label": "PromissoryBalanceAmount", "terseLabel": "Promissory balance amount" } } }, "localname": "PromissoryBalanceAmount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "biot_PublicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PublicMember", "terseLabel": "Public [Member]" } } }, "localname": "PublicMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "domainItemType" }, "biot_PublicWarrantExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrant Expired.", "label": "PublicWarrantExpired", "terseLabel": "Public warrant expired term" } } }, "localname": "PublicWarrantExpired", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "biot_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PublicWarrantsMember", "terseLabel": "(Initial Measurement) Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "domainItemType" }, "biot_PurchasePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PurchasePrice", "terseLabel": "Purchase price per share (in Dollars per share)" } } }, "localname": "PurchasePrice", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "biot_RangeAxisAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RangeAxisAxis", "terseLabel": "Range Axis [Axis]" } } }, "localname": "RangeAxisAxis", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "biot_RangeAxisDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RangeAxis [Domain]" } } }, "localname": "RangeAxisDomain", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "biot_ReceivedProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Received proceeds.", "label": "ReceivedProceeds", "terseLabel": "Received proceeds" } } }, "localname": "ReceivedProceeds", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted" } } }, "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_RedemptionOfPublicSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption of public shares percentage.", "label": "RedemptionOfPublicSharesPercentage", "terseLabel": "Redemption of public shares, percentage" } } }, "localname": "RedemptionOfPublicSharesPercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "biot_RefundOfOverPaymentsOfPromissoryNote": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Refund of over payment of promissory note.", "label": "RefundOfOverPaymentsOfPromissoryNote", "terseLabel": "Refund of over payment of promissory note" } } }, "localname": "RefundOfOverPaymentsOfPromissoryNote", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "biot_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "biot_RelatedPartyTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]" } } }, "localname": "RelatedPartyTransactionsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "biot_RelatedPartyTransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Table]" } } }, "localname": "RelatedPartyTransactionsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "biot_RiskfreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.", "label": "RiskfreeInterestRate", "terseLabel": "Risk-free interest rate" } } }, "localname": "RiskfreeInterestRate", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable" ], "xbrltype": "stringItemType" }, "biot_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RisksAndUncertaintiesPolicyTextBlock", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_SchedulOfProvisionForIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedul of provision for income taxes [Abstract]" } } }, "localname": "SchedulOfProvisionForIncomeTaxesAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_SchedulOfProvisionForbenefitFromIncomeTaxesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SchedulOfProvisionForbenefitFromIncomeTaxesTableTextBlock", "terseLabel": "Schedul of provision for income taxes" } } }, "localname": "SchedulOfProvisionForbenefitFromIncomeTaxesTableTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "biot_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of accrued expenses and other current liabilities [Abstract]" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets that are measured at fair value on a recurring basis [Abstract]" } } }, "localname": "ScheduleOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfAssumptionsUsedForTheValuationOfTheWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assumptions used for the valuation of the warrants [Abstract]" } } }, "localname": "ScheduleOfAssumptionsUsedForTheValuationOfTheWarrantsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfBasicAndDilutedLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of basic and diluted loss per share [Abstract]" } } }, "localname": "ScheduleOfBasicAndDilutedLossPerShareAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfBasicAndDilutedNetIncomePerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of basic and diluted net income per common share [Abstract]" } } }, "localname": "ScheduleOfBasicAndDilutedNetIncomePerCommonShareAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfBinomialLatticeModelForWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of binomial lattice model for warrants [Abstract]" } } }, "localname": "ScheduleOfBinomialLatticeModelForWarrantsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfBlackScholesOptionPricingModelAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of black-scholes option pricing model [Abstract]" } } }, "localname": "ScheduleOfBlackScholesOptionPricingModelAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfBlackscholesOptionPricingModel": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfBlackscholesOptionPricingModel", "terseLabel": "Schedule of black-scholes option pricing model" } } }, "localname": "ScheduleOfBlackscholesOptionPricingModel", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "biot_ScheduleOfChangeInFairValueOfThe2020And2021WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of change in fair value of the 2020 and 2021 Warrants [Abstract]" } } }, "localname": "ScheduleOfChangeInFairValueOfThe2020And2021WarrantsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfChangeInFairValueOfThe2021ConvertibleNoteTrancheObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of change in fair value of the 2021 Convertible Note tranche obligation [Abstract]" } } }, "localname": "ScheduleOfChangeInFairValueOfThe2021ConvertibleNoteTrancheObligationAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfChangesInTheFairValueOfTheContingentConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in the fair value of the contingent consideration [Abstract]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfTheContingentConsiderationAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfChangesInTheFairValueOfTheContingentConsiderationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of changes in the fair value of the contingent consideration.", "label": "ScheduleOfChangesInTheFairValueOfTheContingentConsiderationTableTextBlock", "terseLabel": "Schedule of changes in the fair value of the contingent consideration" } } }, "localname": "ScheduleOfChangesInTheFairValueOfTheContingentConsiderationTableTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "biot_ScheduleOfChangesInTheFairValueOfTheIndemnificationHoldbackAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in the fair value of the indemnification holdback [Abstract]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfTheIndemnificationHoldbackAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in the fair value of warrant liabilities [Abstract]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfCommonStockOnAnAsConvertedBasisForIssuanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of common stock, on an as-converted basis for issuance [Abstract]" } } }, "localname": "ScheduleOfCommonStockOnAnAsConvertedBasisForIssuanceAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfCondensedBalanceSheetAreReconciledAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of condensed balance sheet are reconciled [Abstract]" } } }, "localname": "ScheduleOfCondensedBalanceSheetAreReconciledAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock", "terseLabel": "Schedule of condensed balance sheet are reconciled" } } }, "localname": "ScheduleOfCondensedBalanceSheetAreReconciledTableTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "biot_ScheduleOfConvertiblePreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of convertible preferred stock [Abstract]" } } }, "localname": "ScheduleOfConvertiblePreferredStockAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of deferred tax assets [Abstract]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of diluted net loss per share attributable to common stockholders [Abstract]" } } }, "localname": "ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAndRecognizedAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of financial assets and liabilities measured and recognized at fair value [Abstract]" } } }, "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAndRecognizedAtFairValueAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfFutureMinimumFacilityLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future minimum facility lease payments [Abstract]" } } }, "localname": "ScheduleOfFutureMinimumFacilityLeasePaymentsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfFuturePrincipalPaymentsUnderTheTermLoanAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future principal payments under the term loan agreement [Abstract]" } } }, "localname": "ScheduleOfFuturePrincipalPaymentsUnderTheTermLoanAgreementAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfGrantDateFairValuesOfEmployeeAndNonEmployeeStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of grant-date fair values of employee and non-employee stock options [Abstract]" } } }, "localname": "ScheduleOfGrantDateFairValuesOfEmployeeAndNonEmployeeStockOptionsAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfLossBeforeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of loss before taxes [Abstract]" } } }, "localname": "ScheduleOfLossBeforeTaxesAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock", "terseLabel": "Schedule of basic and diluted loss per share" } } }, "localname": "ScheduleOfNetLossPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "biot_ScheduleOfPropertyAndEquipmentAreStatedAtCostSubjectToAdjustmentsForImpairmentsLessAccumulatedDepreciationAndAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment are stated at cost, subject to adjustments for impairments, less accumulated depreciation and amortization [Abstract]" } } }, "localname": "ScheduleOfPropertyAndEquipmentAreStatedAtCostSubjectToAdjustmentsForImpairmentsLessAccumulatedDepreciationAndAmortizationAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfPropertyAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment, net [Abstract]" } } }, "localname": "ScheduleOfPropertyAndEquipmentNetAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of provides the changes in the fair value of the convertible notes [Abstract]" } } }, "localname": "ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of provides the changes in the fair value of the convertible notes.", "label": "ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesTableTextBlock", "terseLabel": "Schedule of provides the changes in the fair value of the convertible notes" } } }, "localname": "ScheduleOfProvidesTheChangesInTheFairValueOfTheConvertibleNotesTableTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "biot_ScheduleOfStockBasedCompensationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stock-based compensation expense [Abstract]" } } }, "localname": "ScheduleOfStockBasedCompensationExpenseAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfStockOptionPlanExercisedOptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stock option plan exercised option [Abstract]" } } }, "localname": "ScheduleOfStockOptionPlanExercisedOptionAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_ScheduleOfWarrantsToPurchaseSharesOfTheCompanySCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants to purchase shares of the company\u2019s common stock [Abstract]" } } }, "localname": "ScheduleOfWarrantsToPurchaseSharesOfTheCompanySCommonStockAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_SeriesAFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesAFinancingMember", "terseLabel": "Series A financing [Member]" } } }, "localname": "SeriesAFinancingMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_SeriesC1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesC1ConvertiblePreferredStockMember", "terseLabel": "Series C-1 [Member]", "verboseLabel": "Series C-1 Convertible Preferred Stock [Member]" } } }, "localname": "SeriesC1ConvertiblePreferredStockMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "domainItemType" }, "biot_SeriesC1PreferredStockIssuedToSettleIndemnificationHoldbackAssociatedWithAcquisitionOf": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Series preferred stock issued to settle Indemnification Holdback associated with acquisition of in-process research and development.", "label": "SeriesC1PreferredStockIssuedToSettleIndemnificationHoldbackAssociatedWithAcquisitionOf", "negatedLabel": "Series C-1 preferred stock issued to settle Indemnification Holdback associated with acquisition of in-process research and development" } } }, "localname": "SeriesC1PreferredStockIssuedToSettleIndemnificationHoldbackAssociatedWithAcquisitionOf", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "biot_ShareIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "ShareIssued", "terseLabel": "Shares issued" } } }, "localname": "ShareIssued", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "biot_ShareholdersDEFICITEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 (DEFICIT) Equity (Details) [Line Items]" } } }, "localname": "ShareholdersDEFICITEquityDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "stringItemType" }, "biot_ShareholdersDEFICITEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 (DEFICIT) Equity (Details) [Table]" } } }, "localname": "ShareholdersDEFICITEquityDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "stringItemType" }, "biot_ShareholdersDeficitEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareholdersDeficitEquityAbstract", "terseLabel": "Shareholders\u2019 (Deficit) Equity" } } }, "localname": "ShareholdersDeficitEquityAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "biot_SharesExercisablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares exercisable percentage.", "label": "SharesExercisablePercentage", "terseLabel": "Shares exercisable percentage" } } }, "localname": "SharesExercisablePercentage", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "percentItemType" }, "biot_SponsorAgreedToProvideLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sponsor agreed to provide loans.", "label": "SponsorAgreedToProvideLoans", "terseLabel": "Sponsor agreed to provide loans" } } }, "localname": "SponsorAgreedToProvideLoans", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "biot_StockOptionPlanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan [Abstract]" } } }, "localname": "StockOptionPlanAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_StockOptionPlanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option plan , description.", "label": "StockOptionPlanDescription", "terseLabel": "Stock option plan , description" } } }, "localname": "StockOptionPlanDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Details) [Line Items]" } } }, "localname": "StockOptionPlanDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanDetailsScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Details) - Schedule of grant-date fair values of employee and non-employee stock options [Line Items]" } } }, "localname": "StockOptionPlanDetailsScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanDetailsScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Details) - Schedule of grant-date fair values of employee and non-employee stock options [Table]" } } }, "localname": "StockOptionPlanDetailsScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanDetailsScheduleofstockoptionplanexercisedoptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Details) - Schedule of stock option plan exercised option [Line Items]" } } }, "localname": "StockOptionPlanDetailsScheduleofstockoptionplanexercisedoptionLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanDetailsScheduleofstockoptionplanexercisedoptionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Details) - Schedule of stock option plan exercised option [Table]" } } }, "localname": "StockOptionPlanDetailsScheduleofstockoptionplanexercisedoptionTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Details) [Table]" } } }, "localname": "StockOptionPlanDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan [Line Items]" } } }, "localname": "StockOptionPlanLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlan" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan [Table]" } } }, "localname": "StockOptionPlanTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlan" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Tables) [Line Items]" } } }, "localname": "StockOptionPlanTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanTables" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan (Tables) [Table]" } } }, "localname": "StockOptionPlanTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanTables" ], "xbrltype": "stringItemType" }, "biot_StockOptionPlanTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of stock option plan.", "label": "StockOptionPlanTextBlock", "terseLabel": "Stock Option Plan" } } }, "localname": "StockOptionPlanTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlan" ], "xbrltype": "textBlockItemType" }, "biot_StockholdersDeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockholdersDeficitAbstract", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersDeficitAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "biot_SubleaseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease agreement description.", "label": "SubleaseAgreementDescription", "terseLabel": "Sublease agreement, description" } } }, "localname": "SubleaseAgreementDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "biot_SubleaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SubleaseMember", "terseLabel": "Sublease [Member]" } } }, "localname": "SubleaseMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "domainItemType" }, "biot_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "biot_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "biot_SubsequentEventsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]" } } }, "localname": "SubsequentEventsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "biot_SubsequentEventsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Table]" } } }, "localname": "SubsequentEventsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomepercommonshareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income per common share [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomepercommonshareLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomepercommonshareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income per common share [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomepercommonshareTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Tables) [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "biot_SummaryofSignificantAccountingPoliciesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Tables) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement [Abstract]" } } }, "localname": "TermLoanAgreementAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_TermLoanAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of term loan agreement.", "label": "TermLoanAgreementDescription", "terseLabel": "Term loan agreement, description" } } }, "localname": "TermLoanAgreementDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement (Details) [Line Items]" } } }, "localname": "TermLoanAgreementDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementDetailsScheduleoffutureprincipalpaymentsunderthetermloanagreementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement (Details) - Schedule of future principal payments under the term loan agreement [Line Items]" } } }, "localname": "TermLoanAgreementDetailsScheduleoffutureprincipalpaymentsunderthetermloanagreementLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementDetailsScheduleoffutureprincipalpaymentsunderthetermloanagreementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement (Details) - Schedule of future principal payments under the term loan agreement [Table]" } } }, "localname": "TermLoanAgreementDetailsScheduleoffutureprincipalpaymentsunderthetermloanagreementTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement (Details) [Table]" } } }, "localname": "TermLoanAgreementDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementInitialWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TermLoanAgreementInitialWarrantMember", "terseLabel": "Term loan agreement initial warrant [Member]" } } }, "localname": "TermLoanAgreementInitialWarrantMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_TermLoanAgreementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement [Line Items]" } } }, "localname": "TermLoanAgreementLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreement" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TermLoanAgreementMember", "terseLabel": "Term Loan Agreement [Member]" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "biot_TermLoanAgreementSubsequentWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TermLoanAgreementSubsequentWarrantMember", "terseLabel": "Term loan agreement subsequent warrant [Member]" } } }, "localname": "TermLoanAgreementSubsequentWarrantMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_TermLoanAgreementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement [Table]" } } }, "localname": "TermLoanAgreementTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreement" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement (Tables) [Line Items]" } } }, "localname": "TermLoanAgreementTablesLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementTables" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan Agreement (Tables) [Table]" } } }, "localname": "TermLoanAgreementTablesTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementTables" ], "xbrltype": "stringItemType" }, "biot_TermLoanAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TermLoanAgreementTextBlock", "terseLabel": "Term Loan Agreement" } } }, "localname": "TermLoanAgreementTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreement" ], "xbrltype": "textBlockItemType" }, "biot_TheCompanyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company [Abstract]" } } }, "localname": "TheCompanyAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_TheCompanyDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company (Details) [Line Items]" } } }, "localname": "TheCompanyDetailsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "biot_TheCompanyDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company (Details) [Table]" } } }, "localname": "TheCompanyDetailsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "biot_TheCompanyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company [Line Items]" } } }, "localname": "TheCompanyLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompany" ], "xbrltype": "stringItemType" }, "biot_TheCompanyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company [Table]" } } }, "localname": "TheCompanyTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompany" ], "xbrltype": "stringItemType" }, "biot_TheCompanyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the company.", "label": "TheCompanyTextBlock", "terseLabel": "The Company" } } }, "localname": "TheCompanyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompany" ], "xbrltype": "textBlockItemType" }, "biot_TotalAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "TotalAccruedExpensesAndOtherCurrentLiabilities", "terseLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "TotalAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "biot_TotalEquityClassifiedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TotalEquityClassifiedMember", "terseLabel": "Total Equity-Classified [Member]" } } }, "localname": "TotalEquityClassifiedMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_TotalLiabilityclassifiedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TotalLiabilityclassifiedMember", "terseLabel": "Total liability-classified [Member]" } } }, "localname": "TotalLiabilityclassifiedMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_TotalWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TotalWarrantsMember", "terseLabel": "Total warrants [Member]" } } }, "localname": "TotalWarrantsMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "domainItemType" }, "biot_TrancheObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of convertible note tranche obligation.", "label": "TrancheObligation", "terseLabel": "Convertible note tranche obligation" } } }, "localname": "TrancheObligation", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "biot_TrancheObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TrancheObligationMember", "terseLabel": "Tranche obligation [Member]" } } }, "localname": "TrancheObligationMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable" ], "xbrltype": "domainItemType" }, "biot_TransactionCostsOfInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs of stock in the initial public offering.", "label": "TransactionCostsOfInitialPublicOffering", "terseLabel": "Transaction costs" } } }, "localname": "TransactionCostsOfInitialPublicOffering", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "biot_UnamortizedDebtIssuanceCostDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unamortized debt issuance cost description.", "label": "UnamortizedDebtIssuanceCostDescription", "terseLabel": "Unamortized debt issuance cost, description" } } }, "localname": "UnamortizedDebtIssuanceCostDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "biot_UnderwriterDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of Underwriters\u2019 discount.", "label": "UnderwriterDiscount", "terseLabel": "Underwriters discount" } } }, "localname": "UnderwriterDiscount", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "biot_UnderwritingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnderwritingAgreementDescription", "terseLabel": "Underwriting agreement description" } } }, "localname": "UnderwritingAgreementDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "biot_UnrecognizedZaxBenefitBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "UnrecognizedZaxBenefitBalance", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedZaxBenefitBalance", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable" ], "xbrltype": "monetaryItemType" }, "biot_UnvestedEarlyExercisedStockAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested early exercised stock awards.", "label": "UnvestedEarlyExercisedStockAwards", "terseLabel": "Unvested early exercised stock awards" } } }, "localname": "UnvestedEarlyExercisedStockAwards", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "biot_WagesLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "WagesLimit", "terseLabel": "Wages limit" } } }, "localname": "WagesLimit", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "biot_WagesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wages percent", "label": "WagesPercent", "terseLabel": "Wages percent" } } }, "localname": "WagesPercent", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "biot_WarrantLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of warrant liabilities.", "label": "WarrantLiabilities", "terseLabel": "Warrant liabilities" } } }, "localname": "WarrantLiabilities", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "biot_WarrantLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantLiabilitiesMember", "terseLabel": "Warrant Liabilities [Member]" } } }, "localname": "WarrantLiabilitiesMember", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "domainItemType" }, "biot_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantLiabilityPolicyTextBlock", "terseLabel": "Warrant Liabilities" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "biot_WarrantLiabilityPrivatePlacementWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Liability Private Placement Warrants.", "label": "WarrantLiabilityPrivatePlacementWarrants", "terseLabel": "Warrant liability \u2013 Private Placement Warrants" } } }, "localname": "WarrantLiabilityPrivatePlacementWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "biot_WarrantLiabilityPublicWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Liability Public Warrants.", "label": "WarrantLiabilityPublicWarrants", "terseLabel": "Warrant liability \u2013 Public Warrants" } } }, "localname": "WarrantLiabilityPublicWarrants", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "biot_WarrantsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsDescription", "terseLabel": "Warrants, description" } } }, "localname": "WarrantsDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "biot_WarrantsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Disclosure [Abstract]" } } }, "localname": "WarrantsDisclosureAbstract", "nsuri": "http://www.biotechacquisitionco.com/20211231", "xbrltype": "stringItemType" }, "biot_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsDisclosureTextBlock", "terseLabel": "WARRANTS" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "biot_WarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Abstract]" } } }, "localname": "WarrantsLineItems", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Warrants" ], "xbrltype": "stringItemType" }, "biot_WarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants purchase shares.", "label": "WarrantsShares", "terseLabel": "Warrants to purchase shares (in Shares)" } } }, "localname": "WarrantsShares", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "biot_WarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Table]" } } }, "localname": "WarrantsTable", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/Warrants" ], "xbrltype": "stringItemType" }, "biot_WeightedaverageSharesUsedInComputingNetLossPerShareAttributableToCommonSharehold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of weighted-average shares used in computing net loss per share attributable to common shares,", "label": "WeightedaverageSharesUsedInComputingNetLossPerShareAttributableToCommonSharehold", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in Shares)" } } }, "localname": "WeightedaverageSharesUsedInComputingNetLossPerShareAttributableToCommonSharehold", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "biot_WeightedaverageSharesUsedInComputingNetLossPerShareAttributableToCommonStockhold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted.", "label": "WeightedaverageSharesUsedInComputingNetLossPerShareAttributableToCommonStockhold", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "WeightedaverageSharesUsedInComputingNetLossPerShareAttributableToCommonStockhold", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "sharesItemType" }, "biot_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "WorkingCapital", "terseLabel": "Negative working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "biot_WorkingCapitalLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital loans.", "label": "WorkingCapitalLoans", "terseLabel": "Working capital loans" } } }, "localname": "WorkingCapitalLoans", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "biot_convertibleNoteDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "convertibleNoteDescription", "terseLabel": "Convertible note description" } } }, "localname": "convertibleNoteDescription", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "biot_labAndOfficeSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "lab and office space.", "label": "labAndOfficeSpace", "terseLabel": "lease square feet (in Square Meters)" } } }, "localname": "labAndOfficeSpace", "nsuri": "http://www.biotechacquisitionco.com/20211231", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "areaItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "stringItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r126", "r217", "r222", "r228", "r387", "r388", "r395", "r396", "r473", "r581" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy", "http://www.biotechacquisitionco.com/role/AcquisitionofATXCo", "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/BalanceSheetComponents", "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails", "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables", "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesTables", "http://www.biotechacquisitionco.com/role/CommonStock", "http://www.biotechacquisitionco.com/role/CommonStockDetails", "http://www.biotechacquisitionco.com/role/CommonStockTables", "http://www.biotechacquisitionco.com/role/CommonStockWarrants", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/ConvertibleNotes", "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStock", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockTables", "http://www.biotechacquisitionco.com/role/FairValueMeasurements", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables", "http://www.biotechacquisitionco.com/role/IncomeTaxes", "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails", "http://www.biotechacquisitionco.com/role/IncomeTaxesTables", "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreements", "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails", "http://www.biotechacquisitionco.com/role/NetLossPerShare", "http://www.biotechacquisitionco.com/role/NetLossPerShareTables", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2020and2021WarrantsTable", "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable", "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofthecontingentconsiderationTable", "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable", "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable", "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable", "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable", "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable", "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable", "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable", "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable", "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable", "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable", "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable", "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/StockOptionPlan", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/StockOptionPlanTables", "http://www.biotechacquisitionco.com/role/SubsequentEvents", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables", "http://www.biotechacquisitionco.com/role/TermLoanAgreement", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementTables", "http://www.biotechacquisitionco.com/role/TheCompany", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r126", "r217", "r222", "r228", "r387", "r388", "r395", "r396", "r473", "r581" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy", "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/FairValueMeasurements", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SubsequentEvents", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r234", "r268", "r303", "r305", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r549", "r551", "r582", "r583" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r234", "r268", "r303", "r305", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r549", "r551", "r582", "r583" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r234", "r268", "r292", "r303", "r305", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r549", "r551", "r582", "r583" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r234", "r268", "r292", "r303", "r305", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r549", "r551", "r582", "r583" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r187", "r188", "r289", "r290", "r550", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r187", "r188", "r289", "r290", "r550", "r566", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization And Business Operations [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesFairValueDisclosure": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of accrued expenses.", "label": "Accrued Liabilities, Fair Value Disclosure", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts": { "auth_ref": [ "r56", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of debt issuance costs classified as current.", "label": "Accumulated Amortization, Debt Issuance Costs, Current", "terseLabel": "Company incurred loan issuance costs" } } }, "localname": "AccumulatedAmortizationOfCurrentDeferredFinanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r65", "r66", "r67", "r537", "r556", "r557" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities": { "auth_ref": [ "r67", "r190", "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive loss related to portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized as available-for-sale that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.", "label": "Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Available-for-sale, Debt Securities", "terseLabel": "Ending balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64", "r67", "r74", "r75", "r76", "r128", "r129", "r130", "r392", "r552", "r553", "r590" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r336", "r476" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r128", "r129", "r130", "r333", "r334", "r335", "r415" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other.", "label": "APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AdvanceRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.", "label": "Advance Rent", "terseLabel": "Advance Rent" } } }, "localname": "AdvanceRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r307", "r330", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r85", "r104", "r251", "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Abstract]" } } }, "localname": "AssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r380", "r381", "r382", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Total consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "auth_ref": [ "r380", "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "Asset Acquisition [Text Block]", "terseLabel": "Acquisition of ATXCo" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCo" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r119", "r173", "r181", "r185", "r194", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r387", "r395", "r429", "r474", "r476", "r511", "r533" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r57", "r119", "r194", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r387", "r395", "r429", "r474", "r476" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Marketable securities held in Trust Account", "verboseLabel": "Asset held in trust account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r115" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Marketable securities held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r302", "r304" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r302", "r304", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting power, percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.", "label": "Business Combination, Acquired Receivables, Gross Contractual Amount", "terseLabel": "Combination amount" } } }, "localname": "BusinessCombinationAcquiredReceivablesGrossContractualAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "California [Member]" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r17", "r452", "r453" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "terseLabel": "Contingent consideration, current" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r51", "r452", "r453" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Contingent consideration, noncurrent" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r585" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Computer equipment and software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r37", "r476", "r562", "r563" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r37", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents \u2013 Ending", "periodStartLabel": "Cash and cash equivalents \u2013 Beginning" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net Change in Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r107" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r13", "r107", "r509" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r99", "r106", "r112" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "totalLabel": "Total cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:", "verboseLabel": "SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r117", "r119", "r142", "r143", "r148", "r151", "r153", "r159", "r160", "r161", "r194", "r217", "r222", "r223", "r224", "r228", "r229", "r265", "r266", "r270", "r274", "r429", "r588" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "netLabel": "Warrant exercisable per share (in Dollars per share)", "terseLabel": "Warrant price per share (in Dollars per share)", "verboseLabel": "Warrants price per warrants (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of expense or revenue offset related to the warrants or rights.", "label": "Class of Warrant or Right, Expense or Revenue Recognized", "terseLabel": "Warrants. description" } } }, "localname": "ClassOfWarrantOrRightExpenseOrRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of purchased shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Sale of warrants (in Shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding", "verboseLabel": "Warrants to purchase common stock (in Shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r287", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r52", "r214", "r517", "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r211", "r212", "r213", "r215", "r569" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Class A Ordinary Shares [Member]", "netLabel": "Class A [Member]", "terseLabel": "Class A Ordinary Shares", "verboseLabel": "Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Class B Ordinary Shares [Member]", "netLabel": "Class B [Member]", "terseLabel": "Class B Ordinary Shares", "verboseLabel": "Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Remaining shares available for issuance under the Stock Option Plan", "verboseLabel": "Reserved shares" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r128", "r129", "r415" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "netLabel": "Ordinary shares [Member]", "terseLabel": "Ordinary Shares", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value (in Dollars per share)", "verboseLabel": "Common stock, per share (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, shares authorized", "verboseLabel": "Ordinary shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, shares issued", "verboseLabel": "Ordinary shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Ordinary shares, shares outstanding", "verboseLabel": "Ordinary shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r476" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 156,600,925 and 178,329,409 shares authorized at December 31, 2020 and 2021, respectively; 7,887,913 and 10,035,358 shares issued and outstanding at December 31, 2020 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common shares, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "terseLabel": "Common unit issuance" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r69", "r71", "r72", "r79", "r520", "r545" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r164", "r530" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": { "auth_ref": [ "r1", "r126", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.", "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r114", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "auth_ref": [ "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.", "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure", "terseLabel": "Contingent Consideration", "verboseLabel": "Fair value of Contingent Consideration" } } }, "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractuallySpecifiedServicingFeesAmount": { "auth_ref": [ "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "All amounts that, per contract, are due to the servicer in exchange for servicing the financial asset and would no longer be received by a servicer if the beneficial owners of the serviced assets (or their trustees or agents) were to exercise their actual or potential authority under the contract to shift the servicing to another servicer. Depending on the servicing contract, those fees may include some or all of the difference between the interest rate collected on the asset being serviced and the rate to be paid to the beneficial owners of the asset.", "label": "Contractually Specified Servicing Fees, Amount", "terseLabel": "Service charged" } } }, "localname": "ContractuallySpecifiedServicingFeesAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Conversion of Stock [Line Items]" } } }, "localname": "ConversionOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r109", "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Convertible Notes", "verboseLabel": "Conversion of price per share (in Shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockTable": { "auth_ref": [ "r109", "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock [Table]" } } }, "localname": "ConversionOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Convertible notes payable at fair value ($15,103 and $29,168 to related parties, respectively)" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r230", "r231", "r232", "r234", "r242", "r243", "r244", "r247", "r248", "r249", "r250", "r251", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Notes [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r51" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes payable" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r18", "r513", "r534", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "netLabel": "Principal amount", "terseLabel": "Convertible notes issued", "verboseLabel": "Convertible notes" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Current", "terseLabel": "Convertible notes payable at fair value (in Dollars)" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r17", "r512", "r531", "r564" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes [Member]", "verboseLabel": "Senior Convertible Promissory Notes [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r22", "r23", "r277", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible notes will convert into shares (in Shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms": { "auth_ref": [ "r25", "r26", "r27", "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivable reflecting the cost incurred on uncompleted contracts in excess of related billings.", "label": "Costs in Excess of Billings", "terseLabel": "Incurred cost" } } }, "localname": "CostsInExcessOfBillingsOnUncompletedContractsOrPrograms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r120", "r361", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r120", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r120", "r361", "r367", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r120", "r361", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SchedulofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear": { "auth_ref": [ "r109", "r111" ], "lang": { "en-us": { "role": { "documentation": "Expiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction.", "label": "Debt Conversion, Converted Instrument, Expiration or Due Date", "terseLabel": "Effective expiration date", "verboseLabel": "Expiration Date" } } }, "localname": "DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "dateItemType" }, "us-gaap_DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear": { "auth_ref": [ "r109", "r111" ], "lang": { "en-us": { "role": { "documentation": "Date the financial instrument was issued in exchange for the original debt being converted in a noncash or part noncash transaction, in YYYY-MM-DD format.", "label": "Debt Conversion, Converted Instrument, Issuance Date", "terseLabel": "Issue Date" } } }, "localname": "DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "dateItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r109", "r111" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Number of Shares Outstanding and exercisable" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r116", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r245", "r252", "r253", "r254", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r233", "r256" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Exercise Price (in Dollars per share)", "verboseLabel": "Sale of price per share (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "auth_ref": [ "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.", "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "terseLabel": "Issued to convertible note" } } }, "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue": { "auth_ref": [ "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share.", "label": "Debt Instrument, Convertible, Liquidation Preference, Value", "terseLabel": "Convertible Preferred Stock, Liquidation Preference" } } }, "localname": "DebtInstrumentConvertibleLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Conversion price" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r231", "r258", "r259", "r445", "r447", "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Shares exercisable" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Common stock effective date", "verboseLabel": "Merger date" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r242", "r444", "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized debt discount on convertible notes" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r109", "r110", "r111" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Payment of offering costs through the issuance of promissory note", "verboseLabel": "Incurred issuance costs" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-sale, Term", "terseLabel": "Maturity date" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.", "label": "Debt Securities, Current", "terseLabel": "Securities issued amount" } } }, "localname": "DebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred underwriting commission payable" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r16", "r510", "r532" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred Costs, Current", "terseLabel": "Deferred transaction costs" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r345", "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Total deferred income tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r56", "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred transaction costs in accounts payable and accruals" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r20", "r450", "r462" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent, less current portion" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredSalesInducementCostAmortizationExpenseAccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for deferred sales inducement cost from accrued interest on unamortized balance.", "label": "Deferred Sales Inducement Cost, Amortization Expense, Accrued Interest", "terseLabel": "Accrued interest expense" } } }, "localname": "DeferredSalesInducementCostAmortizationExpenseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r359", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Research and development credits carryforwards" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r359", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Fixed assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r358", "r359", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "auth_ref": [ "r359", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other", "terseLabel": "Accruals and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r346", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r359", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Fixed assets" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r104", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expanse" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r104", "r171" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r58", "r61", "r62", "r407", "r489" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Convertible Notes at fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r406" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Transaction cost \u2013 warrants" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r61", "r405", "r408", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r59", "r60", "r61", "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Warrant Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r125", "r400", "r401", "r403", "r404", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Warrant Liability" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfInterestRateDerivativeActivities": { "auth_ref": [ "r400", "r401", "r402", "r403", "r404", "r412" ], "lang": { "en-us": { "role": { "documentation": "General discussion of the entity's interest rate derivative activities.", "label": "Description of Interest Rate Derivative Activities", "terseLabel": "Term loan agreement interest rate, description" } } }, "localname": "DescriptionOfInterestRateDerivativeActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r284", "r528" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Cash" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsShareBasedCompensationCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.", "label": "Dividend, Share-based Payment Arrangement, Cash", "terseLabel": "Noncumulative cash dividends" } } }, "localname": "DividendsShareBasedCompensationCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r44", "r124", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due to Other Related Parties, Current", "terseLabel": "Outstanding promissory note" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r44", "r124", "r220", "r222", "r223", "r227", "r228", "r229", "r468" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Advances from related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r124", "r220", "r222", "r223", "r227", "r228", "r229", "r468", "r516", "r543" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Reduce amount of promissory note" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "netLabel": "Basic and diluted net income per ordinary share", "terseLabel": "Basic and diluted net loss per share, Class A (in Dollars per share)", "verboseLabel": "Basic and diluted net loss per share, Class B (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r154", "r155", "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r435" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.", "label": "Employee Benefit and Share-based Payment Arrangement, Noncash", "terseLabel": "Unrecognized compensation cos (in Dollars)" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.", "label": "Employee Stock Ownership Plan (ESOP), Number of Allocated Shares", "terseLabel": "Employees and non-employees purchased shares" } } }, "localname": "EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_EnvironmentalCostsRecognizedRecoveryCreditedToExpense": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of any recovery from third parties that is credited to environmental remediation costs.", "label": "Environmental Costs Recognized, Recovery Credited to Expense", "terseLabel": "Recognized an expense" } } }, "localname": "EnvironmentalCostsRecognizedRecoveryCreditedToExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r74", "r75", "r76", "r128", "r129", "r130", "r132", "r137", "r139", "r158", "r195", "r281", "r284", "r333", "r334", "r335", "r363", "r364", "r415", "r436", "r437", "r438", "r439", "r440", "r441", "r552", "r553", "r554", "r590" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares issued", "verboseLabel": "Additional shares issued (in Shares)" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": { "auth_ref": [ "r522" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expense related to distribution, servicing and underwriting fees.", "label": "Expense Related to Distribution or Servicing and Underwriting Fees", "terseLabel": "Underwriting fees" } } }, "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r104", "r263" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of convertible notes held at fair value, tranche obligation and warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset and liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings", "terseLabel": "Settlement date fair value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of binomial lattice model for warrants" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r244", "r258", "r259", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r418", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueConcentrationOfRiskEquityMethodInvestments": { "auth_ref": [ "r192" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents disclosure of all significant concentrations of credit risk or market risk arising from the subject financial instrument (as defined), whether from an individual counterparty or groups of counterparties.", "label": "Fair Value, Concentration of Risk, Equity Method Investments", "terseLabel": "Fair value extinguishment" } } }, "localname": "FairValueConcentrationOfRiskEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r244", "r293", "r294", "r299", "r301", "r418", "r480" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "verboseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r244", "r258", "r259", "r293", "r294", "r299", "r301", "r418", "r481" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r244", "r258", "r259", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r418", "r482" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "verboseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Transfer to Level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of change in fair value of the 2020 and 2021 Warrants" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect": { "auth_ref": [ "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date.", "label": "Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect", "terseLabel": "Fair value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of change in fair value of the 2021 Convertible Note tranche obligation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)", "negatedLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Change in fair value of convertible notes" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r244", "r258", "r259", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "terseLabel": "Fair value as of December 31, 2021" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "terseLabel": "Fair value gain on remeasurement" } } }, "localname": "FairValueOptionChangesInFairValueGainLoss1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": { "auth_ref": [ "r522" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.", "label": "Federal Deposit Insurance Corporation Premium Expense", "terseLabel": "Federal depository insurance" } } }, "localname": "FederalDepositInsuranceCorporationPremiumExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalFundsPurchased": { "auth_ref": [ "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short term borrowing where a bank borrows, at the federal funds rate, from another bank.", "label": "Federal Funds Purchased", "terseLabel": "Unrecognized tax benefits comprised" } } }, "localname": "FederalFundsPurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalMinistryOfFinanceGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Germany.", "label": "Federal Ministry of Finance, Germany [Member]", "terseLabel": "Federal [Member]" } } }, "localname": "FederalMinistryOfFinanceGermanyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Excess amount holder divided (in Dollars)" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r431", "r432", "r433", "r434" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency exchange (loss) gain, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r405" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Change in fair value of convertible notes, tranche obligation and warrant liability" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Recognized gain (loss)" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareOrganizationRevenueSourcesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by major payor source of revenue for health care organizations.", "label": "Health Care Organization, Revenue Sources [Axis]" } } }, "localname": "HealthCareOrganizationRevenueSourcesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]", "verboseLabel": "Initial Public Offering [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r199", "r205" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncentiveFeeExpense": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for incentive rights held by the managing member or general partner, of limited liability company (LLC) or limited partnership (LP).", "label": "Incentive Fee Expense", "terseLabel": "Incentive fee" } } }, "localname": "IncentiveFeeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r121", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r77", "r173", "r180", "r183", "r184", "r186", "r508", "r518", "r525", "r546" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r121", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "negatedLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r173", "r180", "r183", "r184", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Total loss before provision for income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoflossbeforetaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r122", "r348", "r352", "r357", "r365", "r370", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r138", "r139", "r172", "r347", "r366", "r371", "r547" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r73", "r343", "r344", "r352", "r353", "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Increase (Decrease) in Derivative Liabilities", "negatedLabel": "Change in fair value of warrants", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "Changes in operating assets and liabilities:", "verboseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred rent liability" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Rent", "negatedLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInPrepaidRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r87", "r250", "r260", "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "terseLabel": "Accrued interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOtherLongTermDebt": { "auth_ref": [ "r524" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs.", "label": "Interest Expense, Other Long-term Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r521" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income \u2013 bank" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeSecuritiesOtherUSGovernment": { "auth_ref": [ "r523" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest income on securities issued by US government agencies not including US Treasury Securities.", "label": "Interest Income, Securities, Other US Government", "terseLabel": "Interest earned on marketable securities held in Trust Account" } } }, "localname": "InterestIncomeSecuritiesOtherUSGovernment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r97", "r101", "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward": { "auth_ref": [ "r559" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed deficit from capital loss carryforward of investment company.", "label": "Investment Company, Distributable Earnings (Loss), Accumulated Capital Loss Carryforward", "terseLabel": "Working capital deficit" } } }, "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyGainLossOnInvestmentPerShare": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit amount of realized and unrealized gain (loss) on investment.", "label": "Investment Company, Gain (Loss) on Investment, Per Share", "terseLabel": "Purchase price per share (in Dollars per share)" } } }, "localname": "InvestmentCompanyGainLossOnInvestmentPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_InvestmentCompanyIncentiveFeeToAverageNetAssets": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Percentage of incentive fee expense to average net assets.", "label": "Investment Company, Incentive Fee to Average Net Assets", "terseLabel": "Incentive fee, percentage" } } }, "localname": "InvestmentCompanyIncentiveFeeToAverageNetAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentCompanyShareholderServiceFeeExpense": { "auth_ref": [ "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent.", "label": "Investment Company, Shareholder Service Fee Expense", "terseLabel": "Service fee" } } }, "localname": "InvestmentCompanyShareholderServiceFeeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r83", "r170" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest earned on marketable securities held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r10", "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "domainItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Contingent fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Operating Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureminimumfacilityleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r119", "r182", "r194", "r217", "r218", "r219", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r388", "r395", "r396", "r429", "r474", "r475" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r34", "r119", "r194", "r429", "r476", "r514", "r540" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 (DEFICIT) EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r119", "r194", "r217", "r218", "r219", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r388", "r395", "r396", "r429", "r474", "r475", "r476" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Unused line fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiquidationBasisOfAccountingRemeasurementGainLossOnAsset": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from remeasurement of an asset to reflect the change in value under liquidation basis.", "label": "Liquidation Basis of Accounting, Remeasurement, Gain (Loss) on Asset", "terseLabel": "Fair value loss on remeasurement" } } }, "localname": "LiquidationBasisOfAccountingRemeasurementGainLossOnAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r243", "r255", "r258", "r259", "r513", "r535" ], "calculation": { "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": { "auth_ref": [ "r126" ], "calculation": { "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": { "auth_ref": [ "r126" ], "calculation": { "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffutureprincipalpaymentsunderthetermloanagreementTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r51" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Term loan payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Manufacturing and laboratory equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredandrecognizedatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r102", "r105" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r68", "r70", "r76", "r78", "r105", "r119", "r131", "r133", "r134", "r135", "r136", "r138", "r139", "r149", "r173", "r180", "r183", "r184", "r186", "r194", "r217", "r218", "r219", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r416", "r429", "r519", "r544" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "biot_NetLossAttributableToCommonShareholdersBasicAndDilutedinDollarsPerShare", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r141", "r144", "r145", "r146", "r147", "r150", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutedlosspershareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r18", "r513", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Initial recognition of tranche obligation upon issuance of 2021 Convertible Notes" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/Scheduleofchangeinfairvalueofthe2021ConvertibleNotetrancheobligationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r43", "r124", "r469" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "terseLabel": "Promissory note \u2013 related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office furniture and fixtures [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "negatedLabel": "Operating and formation costs" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r173", "r180", "r183", "r184", "r186" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Net rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the nature and terms of commitment.", "label": "Other Commitments, Description", "terseLabel": "Description of ownership change" } } }, "localname": "OtherCommitmentsDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency exchange gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherDeferredCostsNet": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.", "label": "Other Deferred Costs, Net", "terseLabel": "Payment of offering costs by the Sponsor in exchange for the issuance of Class B ordinary shares" } } }, "localname": "OtherDeferredCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r82", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Other offering expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expense", "terseLabel": "Administrative and support services" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherUnderwritingExpense": { "auth_ref": [ "r548", "r558" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.", "label": "Other Underwriting Expense", "terseLabel": "Deferred underwriting fee payable" } } }, "localname": "OtherUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r104" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts": { "auth_ref": [ "r284", "r285" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of the issuance of new units of limited partnership interest in a public offering, net of offering costs. This is a parenthetical disclosure.", "label": "Partners' Capital Account, Public Sale of Units Net of Offering Costs", "terseLabel": "Offering costs" } } }, "localname": "PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of unvested common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r95" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of costs to issue convertible notes payable" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r96" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r96" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of deferred transaction costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "terseLabel": "Payments to acquire in process research and development" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r89", "r380", "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Purchase consideration" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToInvestInDecommissioningFund": { "auth_ref": [ "r90" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of investments that will be held in a decommissioning trust fund.", "label": "Payments to Acquire Investments to be Held in Decommissioning Trust Fund", "negatedLabel": "Investment of cash in Trust Account" } } }, "localname": "PaymentsToInvestInDecommissioningFund", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Convertible Preferred Stock, Price Per Share" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "terseLabel": "Convertible preferred stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable", "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r265" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preference shares, par value (in Dollars per share)", "verboseLabel": "Preferred shares, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "netLabel": "Preferred Stock (in Shares)", "terseLabel": "Preference shares, shares authorized", "verboseLabel": "Preferred shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r265" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r476" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preference shares, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020", "verboseLabel": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Outstanding amount" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r35", "r36" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r196", "r197" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "netLabel": "Private Placement Warrants [Member]", "terseLabel": "Private Placement [Member]", "verboseLabel": "Private Placement Warrant [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails", "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible notes payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "negatedLabel": "Class A ordinary shares issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r91" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from sale of Private Placement Warrants" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "negatedLabel": "Proceeds allocated to Public Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLegalSettlements": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for the settlement of litigation during the current period.", "label": "Proceeds from Legal Settlements", "terseLabel": "Cash settlement" } } }, "localname": "ProceedsFromLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherEquity": { "auth_ref": [ "r91" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the issuance of equity classified as other.", "label": "Proceeds from Other Equity", "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid" } } }, "localname": "ProceedsFromOtherEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from promissory note \u2013 related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Payments made on promissory note \u2013 related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r91", "r332" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r68", "r70", "r76", "r98", "r119", "r131", "r138", "r139", "r173", "r180", "r183", "r184", "r186", "r194", "r217", "r218", "r219", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r385", "r390", "r391", "r397", "r398", "r416", "r429", "r525" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r204", "r476", "r527", "r541" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r38", "r204", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Public Utility, Property, Plant and Equipment [Line Items]" } } }, "localname": "PublicUtilityPropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentTable": { "auth_ref": [ "r39", "r584" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Public Utility, Property, Plant and Equipment [Table]" } } }, "localname": "PublicUtilityPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentarestatedatcostsubjecttoadjustmentsforimpairmentslessaccumulateddepreciationandamortizationTable" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r180", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r180", "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r300", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r19", "r449", "r460", "r463", "r464", "r466" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Related Party Transaction, Description of Transaction", "terseLabel": "Related party transaction description" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Advances from related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r300", "r467", "r470", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r465", "r466", "r468", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RentalIncomeNonoperating": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.", "label": "Rental Income, Nonoperating", "terseLabel": "Rental fee" } } }, "localname": "RentalIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r94" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedLabel": "Principal repayments of Term Loan" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Excess amount percentage" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r341", "r494", "r585" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "License payment" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "License and Research and Development Agreements" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/LicenseandResearchandDevelopmentAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r112", "r509", "r536" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r13", "r106", "r112", "r509", "r536" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH TO THE BALANCE SHEET" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r13", "r106", "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalents": { "auth_ref": [ "r112", "r509", "r536", "r567", "r568" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r207", "r208", "r209", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Cost incurred" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r284", "r336", "r476", "r539", "r555", "r557" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r128", "r129", "r130", "r132", "r137", "r139", "r195", "r333", "r334", "r335", "r363", "r364", "r415", "r552", "r554" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsUnappropriated": { "auth_ref": [ "r29", "r118", "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.", "label": "Retained Earnings, Unappropriated", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsUnappropriated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleLeasebackTransactionGrossProceedsFinancingActivities": { "auth_ref": [ "r454", "r455", "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow before closing and debt issuance costs received by a seller-lessee in a sale-leaseback recognized in financing activities.", "label": "Sale Leaseback Transaction, Gross Proceeds, Financing Activities", "terseLabel": "Gross proceeds" } } }, "localname": "SaleLeasebackTransactionGrossProceedsFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds amount" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Aggregate purchase price" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r386", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction", "terseLabel": "Private placement warrant description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails", "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Public offering, shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of changes in the fair value of warrant liabilities", "verboseLabel": "Schedule of changes in the fair value of the indemnification holdback" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of common stock, on an as-converted basis for issuance" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of loss before taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfConversionsOfStockTextBlock": { "auth_ref": [ "r109", "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.", "label": "Schedule of Conversions of Stock [Table Text Block]", "terseLabel": "Schedule of convertible preferred stock" } } }, "localname": "ScheduleOfConversionsOfStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "terseLabel": "Schedule of assumptions used for the valuation of the warrants" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured and recognized at fair value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]", "terseLabel": "Schedule of future minimum facility lease payments" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of future principal payments under the term loan agreement" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r39", "r584" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Public Utility Property, Plant, and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment are stated at cost, subject to adjustments for impairments, less accumulated depreciation and amortization" } } }, "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r311", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option plan exercised option" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of grant-date fair values of employee and non-employee stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r287", "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrants to purchase shares of the company\u2019s common stock" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r174", "r175", "r176", "r177", "r178", "r179", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock [Member]", "verboseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Business Combination [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServicingAssetAtAmortizedValueFairValue": { "auth_ref": [ "r414", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.", "label": "Servicing Asset at Amortized Cost, Fair Value", "terseLabel": "Fair value issuance" } } }, "localname": "ServicingAssetAtAmortizedValueFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SettlementLiabilitiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.", "label": "Settlement Liabilities, Current", "negatedLabel": "Settlement in cash" } } }, "localname": "SettlementLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r103" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "weighted-average grant date fair value per share (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "verboseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted-average expected volatility", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "terseLabel": "Weighted Average Shares Available for Grant, Repurchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "terseLabel": "Weighted Average Shares Available for Grant, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "negatedLabel": "Weighted Average Shares Available for Grant, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Weighted Average Shares Available for Grant, Ending Outstanding", "periodStartLabel": "Weighted Average Shares Available for Grant, Beginning Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Weighted Average Shares Available for Grant, Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Weighted Average Number of Options Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Weighted Average Number of Options Outstanding, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Weighted Average Number of Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Weighted Average Aggregate Intrinsic Value, Exercisable (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r313", "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Weighted Average Number of Options Outstanding, Ending Outstanding", "periodStartLabel": "Weighted Average Number of Options Outstanding, Beginning Outstanding", "terseLabel": "Outstanding stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable", "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending Outstanding (in Dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, Beginning Outstanding (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Intrinsic value (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r306", "r331" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Weighted Average Exercise Price, Exercised (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Repurchased (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r308", "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "netLabel": "Purchase price (in Dollars per share)", "terseLabel": "Share price (in Dollars per share)", "verboseLabel": "Per share (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Weighted Average Aggregate Intrinsic Value, Ending Outstanding (in Dollars)", "periodStartLabel": "Weighted Average Aggregate Intrinsic Value, Beginning Outstanding (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r326", "r337" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted-average expected term (years)", "verboseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years), Beginning Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years), Ending Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares issued (in Shares)", "netLabel": "Common stock shares", "terseLabel": "Additional ordinary shares (in Shares)", "verboseLabel": "Founder shares are no longer subject to forfeiture (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/StockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Share price per unit (in Dollars per share)", "verboseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, the maximum amount borrowed at any time during the period.", "label": "Short-term Debt, Maximum Amount Outstanding During Period", "terseLabel": "Outstanding amount" } } }, "localname": "ShorttermDebtMaximumAmountOutstandingDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r113", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SponsorFees": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.", "label": "Sponsor Fees", "terseLabel": "Offering and formation costs" } } }, "localname": "SponsorFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r117", "r119", "r142", "r143", "r148", "r151", "r153", "r159", "r160", "r161", "r194", "r217", "r222", "r223", "r224", "r228", "r229", "r265", "r266", "r270", "r274", "r281", "r429", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConvertibleNotesDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/FairValueMeasurementsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable", "http://www.biotechacquisitionco.com/role/ScheduleofconvertiblepreferredstockTable", "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquityDetails", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r55", "r74", "r75", "r76", "r128", "r129", "r130", "r132", "r137", "r139", "r158", "r195", "r281", "r284", "r333", "r334", "r335", "r363", "r364", "r415", "r436", "r437", "r438", "r439", "r440", "r441", "r552", "r553", "r554", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails", "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ConvertiblePreferredStockDetails", "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofassumptionsusedforthevaluationofthewarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable", "http://www.biotechacquisitionco.com/role/ScheduleofwarrantstopurchasesharesofthecompanyscommonstockTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r128", "r129", "r130", "r158", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow", "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r23", "r24", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Repurchase of common stock (in Shares)", "verboseLabel": "Purchase of shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r246", "r281", "r282", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Series B preferred stock to common stock (in Shares)", "verboseLabel": "Settlement in Series C-1 convertible preferred stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueoftheindemnificationholdbackTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r281", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "netLabel": "Shares issued (in Shares)", "terseLabel": "Issuance of Class B ordinary share to Sponsor (in Shares)", "verboseLabel": "Issuance of shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Private Placement Warrants" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "terseLabel": "Shares subject to forfeiture (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r281", "r284", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Weighted Average Number of Options Outstanding, Exercised", "terseLabel": "Issuance of common stock upon the exercise of options (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofstockoptionplanexercisedoptionTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r281", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of Series B preferred stock to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r281", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Class B ordinary share to Sponsor", "verboseLabel": "Proceeds from issuance 2021 convertible notes and warrants" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Sale of 6,000,000 Private Placement Warrants" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r23", "r24", "r281", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of early exercised shares and restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r55", "r281", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Employee and non-employee stock options [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofgrantdatefairvaluesofemployeeandnonemployeestockoptionsTable" ], "xbrltype": "domainItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r104" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Transaction costs incurred in connection with IPO" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "terseLabel": "Reduce shared (in Shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AcquisitionofATXCoDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Value", "negatedLabel": "Accretion for Class A ordinary shares to redemption amount" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r23", "r24", "r281", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "terseLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r32", "r33", "r119", "r189", "r194", "r429", "r476" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Shareholders\u2019 (Deficit) Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet", "http://www.biotechacquisitionco.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r118", "r266", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r284", "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS\u2019 (DEFICIT) EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ShareholdersDEFICITEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Common stock options issued and outstanding under the Stock Option Plan" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r458", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubscriptionArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue by arrangement wherein a subscribers pay in advance for media (TV, newspaper, magazine, internet), which will generally be recognized as revenue as the media is delivered.", "label": "Subscription Arrangement [Member]", "terseLabel": "Subscription Arrangement [Member]" } } }, "localname": "SubscriptionArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventDescription": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.", "label": "Subsequent Event, Description", "terseLabel": "Subsequent event, description" } } }, "localname": "SubsequentEventDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r442", "r478" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r442", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails", "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r442", "r478" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsDate": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format.", "label": "Subsequent Event, Date", "terseLabel": "Maturity date" } } }, "localname": "SubsequentEventsDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEventsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r477", "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://www.biotechacquisitionco.com/role/InitialPublicOfferingDetails", "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails", "http://www.biotechacquisitionco.com/role/RelatedPartyTransactionsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofbinomiallatticemodelforwarrantsTable", "http://www.biotechacquisitionco.com/role/ScheduleofchangesinthefairvalueofwarrantliabilitiesTable", "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "terseLabel": "Accretion for Class A ordinary shares subject to redemption amount" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r217", "r222", "r223", "r224", "r228", "r229" ], "calculation": { "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Class A ordinary shares subject to possible redemption, 23,000,000 shares and no shares at redemption value at December 31, 2021 and 2020, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Allocation of net income (loss), as adjusted" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityOtherChanges": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other.", "label": "Temporary Equity, Other Changes", "terseLabel": "Class A ordinary shares subject to possible redemption" } } }, "localname": "TemporaryEquityOtherChanges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcondensedbalancesheetarereconciledTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r12", "r264" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value (in Dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Convertible preferred stock, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Convertible preferred stock, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Convertible preferred stock, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Outstanding common stock warrants" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_USGovernmentSecuritiesAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "US Government Securities, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "USGovernmentSecuritiesAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized debt discount" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/TermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r342", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Interest expense accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofprovidesthechangesinthefairvalueoftheconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r162", "r163", "r165", "r166", "r167", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantExercisePriceDecrease": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Decrease", "terseLabel": "Warrant price per share" } } }, "localname": "WarrantExercisePriceDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/PrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/CommonStockWarrantsDetails", "http://www.biotechacquisitionco.com/role/ScheduleofblackscholesoptionpricingmodelTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted average shares outstanding of Class B ordinary shares (in Shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average shares outstanding of Class A ordinary shares (in Shares)", "verboseLabel": "Basic and diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ConsolidatedIncomeStatement", "http://www.biotechacquisitionco.com/role/ScheduleofbasicanddilutednetincomepercommonshareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation", "terseLabel": "Total outstanding common stock and options and remaining shares available" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.biotechacquisitionco.com/role/ScheduleofcommonstockonanasconvertedbasisforissuanceTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04(Schedule I))", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=120391182&loc=d3e5864-122674" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284427-111562" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13296-110859" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(c)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(c)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(c)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=77885742&loc=SL35686336-199416" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=7516967&loc=d3e66267-113978" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45023-112735" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "50", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386837&loc=d3e51831-112757" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386837&loc=d3e51840-112757" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386837&loc=d3e51843-112757" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918703-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123417830&loc=SL77919784-209982" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r472": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r479": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122596-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55302-109406" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.2)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.8)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(ii))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "720", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=d3e9145-115832" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=25866437&loc=d3e10342-115837" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=25866437&loc=d3e10246-115837" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(c)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r586": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r587": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r588": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r589": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" } }, "version": "2.1" }